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This thesis for the first time in the literature, through a single cohort (n=82), 
systematic review and meta-aggregation of the data, has identified that the 
majority (>85%) of ruptured abdominal aortic aneurysm (rAAA) do not present 
with coagulopathy. In addition, the thesis for the first time, through a retro and 
prospective cohort study, has demonstrated that the hemostatic resuscitation 
protocols derived from military and civilian trauma for the correction of 
coagulopathy with a blood product ratio of one unit of packed red blood cell to 
one unit of fresh frozen plasma to one pool of platelet (1:1:1), contributes to 
increased postoperative (30-day) morbidity and mortality, especially thrombotic 
complications. This was attributed to different baseline demographics, 
pathophysiology and coagulation status. Through a comparative study, the 
thesis then confirms that such transfusion practice not only contributes to 
adverse outcomes, but also has no impact on final coagulation status of rAAAs. 
In addition, through a retro and prospective cohort study, a novel hematological 
marker (neutrophil to lymphocyte ratio) (NLR) was identified as an independent 
predictor of morbidity in rAAAs. This thesis was set on the background of 
significant research into all factors that could contribute to pathogenesis, 
inhibition and progression of rAAAs. 
This thesis concludes that the use of additional blood products (fresh frozen 
plasma and platelet) in hemostatic resuscitation of ruptured abdominal aortic 
aneurysms alongside packed red blood cell is not evidence based and a single 
protocol derived from one cohort (military and civilian trauma) of patients does 
not apply to another. The use of additional products in ruptured abdominal aortic 
aneurysms should be tailored to the individual hematological and clinical 
requirements and not as a part of a set transfusion ratio (1:1:1). This thesis has 
resulted in a change of practice and has created a platform for further search of 
the optimal transfusion protocol in this cohort of patients. 
 
Keywords: Ruptured Abdominal Aortic Aneurysm (rAAA); Blood Transfusion; 
Coagulation status; Coagulopathy; Mortality; Morbidity. 
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CHAPTER 1 
Introduction to Abdominal Aortic Aneurysm &Their 
Rupture. 
 
 
1.1 Brief History  
 
The word aneurysm originates from the Greek word “Aneurysma” 
describing permanent cardiac or vessel dilatation. The most common site 
of arterial aneurysm is the infra-renal abdominal aorta (Johnston, 1991; 
Cervantes, 2003). The first description of the aortic aneurysm or so-called 
“tumor of the artery” was found in one of the oldest medical documents 
called “Eber Papyrus” around 1500 BC. Since then, various unsuccessful 
suggestions and attempts have been made by different physicians to 
repair the infra-renal abdominal aorta aneurysms (AAA) (Cohen, 1990). 
Amongst them, the most famous attempt was the wrapping of Albert 
Einstein’s aneurysm with “cellophane” that never prevailed. It was not until 
1951, when two surgeons (Freeman and Dobust, 1952) within the time 
frame of one month in different continents managed to successfully repair 
the infra-renal abdominal aortic aneurysm by a synthetic tube graft. This 
technique (open repair) remained the only method of repair until the 
introduction of endovascular aneurysm repair (EVAR) by Volodos (1986) 
and its later modification by an Argentinian surgeon Parodi in 1999. 
Currently, both techniques (EVAR and open repair) remain the only 
method of treatment for AAAs. Despite advances in the field of EVAR and 
it is associated technology; open technique remains the commonest 
surgical approach in the repair of ruptured abdominal aortic aneurysms. 
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1.2 Epidemiology  
The current reported incidence of AAA occurrence in the population is 
around 4.9-9.9%. Its elective repair has a mortality of 1-5% in tertiary 
vascular centers and up to 10 % in district general hospitals. Once the 
AAA ruptures, the mortality can rise to 50-80%. This is amongst the 
patients that make it to the hospital. 
Currently, in United States (US), ruptured AAA (rAAA) claims 15,000 lives 
every year, and it is the 13th leading cause of death in US. In the United 
Kingdom (UK), rAAA accounts for 8,000 deaths annually (Melton, 1984; 
Holt, 2007). As mentioned earlier, there appears to be a clear familial 
(genetic) link for AAA. Estimated risk of AAA in first-degree relatives is 
11.6 times higher than the rest of the non-affected population. A 
screening process of siblings of aneurysm patients has shown 6 % of 
sisters and 29% of brothers to have aneurysm too (Bird, 1995). AAA 
possesses a 2:1 male to female ratio at any given age. In addition, there 
appears to be a higher incidence of AAA in the Caucasian population in 
comparison to Afro-Caribbean ethnic backgrounds (Salem, 2009). 
 
 
1.3 Terminologies & Anatomy 
 
The native infra-renal aortic diameter in the healthy male population at its 
largest measures approximately 24 mm and this value is 22 mm in the 
female cohort (Wanhainen, 2008). Overall, the female population exhibits 
a smaller aortic diameter but the relative aortic diameter based on the 
predicted size in relation to overall body surface area, exhibits a much 
larger native aorta than their male counterparts (Länne, 1998). Once the 
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infra-renal aorta reaches 1.5 times of its mentioned size, the term 
aneurysm is applied, if the enlargement remains below this threshold, the 
term “Ectasia” is used. If this affects the entire circumference of the artery 
the term “Fusiform” and if partially, the term “Saccular” is applied. Each 
artery including the abdominal aorta is comprised of three major layers; 
The Tunica intima (inner most layer), Tunica media and Tunica adventitia.  
The aneurysmal degeneration of any artery involves all the three layers. 
Tunica intima is composed of multi-functional single layer endothelial cells 
whereas tunica media contains smooth muscle cells, elastin (12%) and 
collagen fibers.  Tunica adventitia contains connective tissue and vasa 
vasorum (Rutherford, 2010).  
 
The current cut off size for the repair of non-ruptured AAA is based on two 
major prospective randomized trials. Both trials suggest that AAA 
measuring 5-5.5 cm should be repaired as the rupture ratio at this level 
remains at 1% per annum. If the AAA reaches 5.5-5.9 cm in size, the 
incidence of rupture increases to about 9.4%. This trend continues as the 
AAA continues to grow in size (Kingdom & Lederle, 2002). 
 
1.4 Pathophysiology 
 
The most common etiology (90%) behind infra-renal abdominal aortic 
aneurysm formation is atherosclerotic degeneration. The second most 
common etiology is an inflammatory process (5%) whereas infectious 
(mycotic) and autoimmune disease plays a less attributing role. The 
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details of all accepted and suggested etiologies are tabulated in Table 1.1 
of this manuscript (Kordzadeh, 2013). 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1 Aetiology of Abdominal Aortic Aneurysm (AAA). 
 
The current evidence suggests that the path to arterial wall remodeling 
(aneurysm formation) is a sequence of multiple pathological factors that 
result in endothelial dysfunction, proteolytic degradation, destruction of 
the elastic media, depletion of vascular smooth muscle cells and 
inflammation of the aortic wall components at both the macro and micro 
level. The initiating trigger is believed to be the consequence of alterations 
in wall shear stress (WSS) due to flow changes (high versus low) 
(Tanweer, 2014). This process creates a unique hemodynamic and 
mechanical insult to the aorta and ignites the aneurysmal pathogenesis. 
Aetiology Percentage 
• Degenerative (atherosclerosis) 
• Inflammatory (Vasculitis). 
• Infective (Mycotic). 
         Fungal. 
         Bacterial (Staphylococcus Species, 
         Streptococcus Species,  
         Non-typhoidal Salmonellae Species, 
         Sexual transmitted disease). 
         Viral. 
         Poly-microbial.  
 
• Autoimmune/ Genetic Disorders. 
         Marfan Syndrome. 
         Loeys-Dietz syndrome.  
         Ehlers-Danlos syndrome.  
         Turner syndrome. 
         Genetic Mutation. 
 
• Traumatic 
90% 
5% 
2% 
 
 
 
 
1% 
 
 
 
1% 
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The cascade of events occurs mostly in the tunica media and intima. In 
this process the endothelial cell damage along with smooth muscle cell, 
elastic and collagen destruction is accelerated by enhanced 
metalloproteinase (MMP) and other proteinase expressions. In such 
circumstances, elastin reduces from 12% in a healthy aorta to 1% only. 
The commonest MMPs associated with AAA are MMP 2 (Gelatinase A) 
and MMP 9 (Gelatinase B) that exhibit elastolytic and proteolytic features 
(Dilme, 2014). Despite the clear understanding of the cellular 
pathogenesis, the exact mechanism of aneurysm formation remains 
undetermined to this date (Table 1.2). 
 
    
 
 
Table 1.2 Process of Rupture in AAAs. 
 
 
1.Atherosclerosis/ Inflammation/ Infection/Trauma 
 
2.Activation of inflammatory pathway. 
Damage to vessel wall (intima /media /intima). 
Recruitment of inflammatory cells. 
 
3.Smooth muscle cell, Elastic and collagen destruction. 
Enhanced metalloproteinase (MMP-9 & MMP-2) 
Activation of proteinases expressions. 
 
4.Elastin reduction to 1%. 
Elastolytic and proteolytic enhancement. 
Endothelial dysfunction. 
Depletion of vascular smooth muscle cells. 
Overall wall weakness. 
 
5.Hemodynamic (pressure & flow) exceed wall strength. 
Focal dilatation of the Aorta. 
 
6.Impact of genetic and risk factors on further growth. 
 
7.Rupture. 
(Once the pressure exceeds wall strength) 
(Beyond 5-5.5 cm). 
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Precipitating Risk Factors 
Advancement in vascular biology has led to a better understanding of the 
ongoing degeneration of AAA at a molecular, cellular and systemic level. 
This, in conjunction with the recent development in pharmacological 
therapies aimed at associated risk factors, could serve as an important 
strategic tool for control or limitation of AAA expansion. Hence, in this 
review, each associated risk factor will be discussed with their respective 
management strategy (Table 1.3). In addition, the role of novel therapies 
in inhibition of AAA growth will be discussed in further detail (Table 1.4).  
 
1.1 Literature Search  
An electronic and comprehensive search of literature in Medline from 
1966 to December 2015 using the following keywords and/or Medical 
Subject Headings (MeSH) terms were used: Abdominal aortic aneurysm 
growth and/or risk factors and/ or genetic disposition, abdominal aortic 
aneurysm and/or sac expansion and/or risk factors. This search was 
limited to adult subjects and English language only. The references were 
also crosschecked for any additional literature not identified in the primary 
search. This search produced a total of 134 articles. All abstracts were 
retrieved and reviewed. 
 
1.2 Publication Selection   
The following restrictions (exclusion criteria) were applied:  
1). Studies with less than 50 cases.  
2). Abstracts and/or conference proceedings.  
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3). Narrative and/or invited review articles. 
4). Studies with no endpoints. 
5). Non abdominal aortic aneurysm studies. 
6). Post aneurysm repair sac expansion.  
 
1.3 Results 
After the application of the inclusion criterion a total of 21 articles were 
found eligible for this review. Outcomes of each article were presented 
with their respective headings and meta-aggregation in a tabulated 
format.   
 
1.4 Diabetes Mellitus 
Diabetes mellitus (DM) is a well-established risk factor for atherosclerotic 
arterial disease but interestingly DM plays a protective role in AAAs. This 
has been attributed to increase synthesis and decrease degradation of 
the matrix metalloproteinase (MMP) resulting in thicker aortic wall. Hence 
reducing growth and rupture incidence. This is believed to be the direct 
result of hyperglycemia in this cohort of patients (Shantikumar, 2010). 
 
1.5 Smoking  
Smoking remains as one of the most relevant risk factors in AAAs growth 
and subsequent rupture. There exists a 2.5-fold increase in smokers 
versus non-smokers (Lederle, 2003). It appears that Tobacco and one of 
its contents Nicotine, can induced MMP-2 through the activation of protein 
kinase alpha-2 resulting in enhanced arterial degeneration and 
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remodeling (Murphy, 1998). Therefore, an aggressive approach in 
smoking cessation plays a crucial role in early inhibition of aneurysm 
growth and its subsequent rupture. 
 
1.6 Chronic Obstructive Pulmonary Disease (COPD) 
Although the majority of COPD in the AAA cohort is smoking related, 
evidence suggests that COPD remains an important risk factor well 
beyond the smoking point (Meijer, 2012). This might be related to the 
impact of significant reduction in forced expiratory volume 1 to that of 
forced expiratory volume (FEV1/FEV) in AAA patients compared to non 
COPD group. This reduction has shown to enhance MMP 2 and 
neutrophil elastase (proteolytic enzymes) expression thus enhancing 
aneurysmal degeneration (Meijer, 2012). 
 
1.7 Renal Failure  
In recent years there has been an accumulating level of evidence to 
support the independent role of renal insufficiency (RI) and raised 
estimated Glomerular Filtration Rate (eGFR) in the prediction of vascular 
events in peripheral vascular disease (Go, 2004). Despite known impacts 
of RI and raised eGFR on small to medium arteries, such impact on AAA 
(large artery) remains contentious. In addition, no direct impact between 
MMPs and renal failure has yet been established. 
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1.8 Hypertension 
Hypertension is a well-established and an independent risk factor for 
rupture of AAAs (Vardulaki, 200). Each cardiac cycle produces a discrete 
quanta of energy, which result in oscillation, loading and unloading of 
elastin and collagen fibers permitting a considerable expandability of the 
normal aorta within normal blood pressure (Wixon, 2009). However, due 
to a significant reduction of such fibers (12% to 1%) in a deformed and 
aneurysmal aorta, exceeding blood pressure (≥ 100mmHg) results in 
stiffening of the aorta and further recruitment of non-distensible fibers 
precipitating rupture (Kordzadeh, 2013). Therefore, a well-controlled blood 
pressure in conjunction with life style modifications to achieve this, is of 
vital importance.  
 
1.9 Atmospheric Pressure 
Current literature suggests that periods of low atmospheric pressure (AP) 
(meteorological parameter) irrespective of the day, season and month 
have a direct correlation to higher incidence of sudden rupture. This has 
been attributed to alteration in partial pressure of oxygen (Po2) and 
carbon dioxide (Pco2) along with changes in main arterial blood pressure. 
The combination of hypoxia, hypercarbia and reduction in blood pressure, 
activates the sympathetic stimulation, enhancing the intra and extra 
luminal arterial pressure and subsequent rupture (Koner, 1989). Despite 
various postulated hypothesis the exact mechanism of rupture in 
correlation to AP remains unknown (Koner, 1989). 
 
 10  
1.10 Vitamin D (25-hydroxyvitamin D) 
Another recently identified risk factor has been low levels of circulating 
plasma Vitamin D (25-hydroxyvitamin D). It appears that in a population-
based study of three hundred and eleven older man, low levels of Vitamin 
D remained an independent risk factor in the enlargement of AAAs. In 
addition, this study also demonstrated a dose-response relationship 
between AAA diameter and vitamin D supplementation. The only set back 
of this study was the lack of calcium and parathyroid circulatory levels that 
are known to have a direct relationship to Vitamin D levels (Wong, 2013).  
 
1.11 Selenium  
Another recently recognized serum marker associated with AAA 
degeneration and enlargement has been low levels of selenium (Se). In 
this study seventy-three individuals (n=73), based on their aneurysm size, 
were categorized to three groups and their respective serum Se were 
obtained. The higher AAA size was associated with lower levels of 
circulatory Se. In Addition, an inverse relationship was observed between 
serum Se and AAA diameter. Hence, suggesting Se might have an 
independent impact on molecular degeneration of AAAs (Witkowska, 
2006).  
 
1.12 Cholesterol 
High levels of cholesterol remain an independent risk factor for the 
atherosclerotic change of abdominal aorta and aneurysmal degeneration. 
Literature suggests low-density lipoprotein (LDL) cholesterol acts via 
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inflammatory mediated pathway in matrix degeneration of the abdominal 
aorta and contribute further to their expansion. Therefore, initiation of 
statins (HMG-CoA reductase) upon diagnosis of AAA remains essential to 
inhibit their further growth (Hobbs, 2003; Kerati, 2004).  
 
 
Table 1.3 Risk Factors Associated with AAA Expansion & Targeted Therapies. 
 
1.13 Gender & Age 
The male population tends to present at a younger age and demonstrate 
a better outcome (Mortality & Morbidity) in comparison to female cohort. 
Overall, there is insidious difference in diagnosis, intervention and 
outcome of rAAA in female compared to male individuals. The most 
Risk Factor Impact  Targeted Therapy 
Smoking • 2.5 fold increase in 
expansion & 
rupture. 
• Smoking cessation 
(Varenicline) 
COPD • Enhances 
degenerative 
changes & 
expansion. 
• Control of COPD 
Hypertension • Increase aortic wall 
stiffness, reduction 
in elastin fibers.  
• Regular monitoring and 
medication  
(ACE Inhibitors & 
Ang II receptor blockers). 
Low Vitamin D • Enhances 
expansion  
• Multivitamins & Sun 
exposure  
Low Selenium • Enhances 
expansion 
• Multivitamins 
Cholesterol &LDL • Enhances 
expansion through 
matrix degeneration 
• Statins (HMG-CoA 
reductase) 
Renal Failure • No impact on large 
vessels. 
• None 
Diabetes Mellitus • Inhibitor of Growth • Normo-glycemic control 
Female Gender and old 
Age 
 
• Worse outcome  • Informed consent. 
Low atmospheric pressure • Higher rupture 
incidence  
• Prioritization of AAA in 
such season.   
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widespread accepted explanation to date has been the protective impact 
of endogenous estrogen on cardiovascular disease in female patients.  It 
has been demonstrated that estrogen inhibits the aneurysmal 
degeneration and negative remodeling of the aorta. This effect eventually 
wears off at the menopausal stage and hormone replacement therapy has 
failed to achieve same result in vitro studies (Makrygiannis, 1964).   
 
1.14 Neutrophil to Lymphocyte (NLR) 
 
A recently identified marker of morbidity and mortality in cardiovascular 
surgery is the hematological marker of neutrophil to lymphocyte ratio (NLR) 
(Duffy, 2006). The Neutrophil to Lymphocyte ratio (NLR) was first reported 
in 1967, is a widely used marker of systemic inflammatory response in 
recent literature (Bobb, 1967). The NLR has been linked to adverse 
outcomes in patients with colorectal, gastric, pancreatic, ovarian and 
hepatocellular carcinoma (Gomez, 2008; An, 2010; Malietzis, 2013).  
 
In relation to vascular surgery, there is a single study that demonstrates 
NLR is a predictor of 2-year survival in patients undergoing a range of 
vascular interventions (Bhutta, 2011). In addition, a recent report suggests 
that in the elective group of AAAs, a preoperative NLR> 5 could be a 
predictor of 30-day mortality (Appleton, 2014). Neutrophilia has been 
associated with collagen remodeling, direct endothelial cell injury, pro-
thrombotic state and hypercoagulability which is known to occur in rAAAs 
(Siminiak, 1995; Madjid, 2004; Coller, 2005). Lymphocytopenia appears 
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to be the result of redistribution and margination of lymphocytes within the 
lymphatic system and a marker of accelerated apoptosis. Low lymphocyte 
count indicates a state of immunosuppression and physiological stress 
that have adverse relation to overall patient outcome (Evans, 1995). 
However, this has never been assessed for ruptured AAAs to date. 
 
Novel Therapies Inhibiting AAA Growth 
 
1.1 Antibiotic therapy  
In the last decade there has been suggestions that atherosclerotic plaque 
in the wall of abdominal aortic aneurysm often contains bacterial 
pathogens and early initiation of antibiotics may aid in the regression or 
inhibition of the aneurysm growth. Two randomized clinical trials, 
demonstrated doxycycline (150 mg daily) and roxithromycin (300mg daily) 
to inhibit aneurysm expansion but this was only effective in the first year 
of treatment and beyond that time frame no further effect was noted 
(Mosorin and Vammens, 2001). Rapamycin an immunosuppressive agent 
in a recent trial has shown 40% reduction in aneurysm expansion through 
reduction of Matrix metalloproteinase (MMP-9) expression (Lawrence, 
2004) (Table 1.4).      
 
1.2 Anti-inflammatory agents  
Increased production of prostaglandins in the process of inflammation 
induces Matrix metalloproteinase production, which plays a significant role 
in expansion of the aneurysm. A recent study by Walton et al. 
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demonstrated that Celecoxib, a COX-2 inhibitor (non-steroidal anti-
inflammatory, cyclooxygenase type 2) significantly decreases the 
incidence and severity of AAA formation. This effect was not similar in 
COX-1 inhibitors (Walton,1999; King, 2006) (Table 1.4). 
 
 
 
Table 1.4 Novel therapies in inhibition of AAA growth. 
 
1.3 Mast Cell inhibitor  
Mast cell stabilizers or inhibitors traditionally used for control of allergic 
disorders and bronchial asthma have shown promising outcome in 
reduction of aortic expansion by 40%. Amongst suggested medication is 
Cromolyn Sodium that inhibits histamine and macrophages in the process 
of the inflammation that in turn reduces MMP expression (Sun, 2007) 
(Table 1.4).   
 
 
Therapy Impact Medication Types 
Antibiotic therapy • Atherosclerotic Plaque. 
• 40% reduction  
(MMP-9). 
• Doxycycline 150mgs. 
• Roxithromycin 
300mgs. 
• Rapamycin  
Anti-inflammatory  
Therapy 
• Prostaglandins. 
• Induces MMP-9 
• Celecoxib (COX-2 
inhibitor). 
 
Mast cell Inhibitor  • Reduces MM 
expression. 
• Reduction of AAA 
expansion by 40%. 
• Cromolyn Sodium  
 
Kinase Inhibitor  
(c-Jun N-terminal kinase ) 
(JNK) 
• Molecular protein in 
apoptosis. 
• Cell differentiation & 
Proliferation.  
• JNK inhibitors. 
Genome Therapy • Genome regulation & 
expression. 
• Inhibition of genome 
transactivation. 
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1.4 Kinase inhibitors  
Kinase or so called c-Jun N-terminal kinases (JNK), a molecular protein 
that play a crucial part in apoptosis, cell differentiation and proliferation 
reacts to inflammatory changes as a result of stress stimuli, shock and 
cytokines. Presence of AAA has shown elevated levels of JNK that 
contribute to pro-inflammatory and MMP-9 activation. The JNK-Inhibitors 
not only reduce the inflammatory changes in AAA patients but also aid in 
restoration of aortic tissue (Yoshimura, 2005) (Table 1.4).  
 
1.5 Genome therapy 
In recent years there has been a significant emphasis on gene regulation 
and expression therapies. The transcription of a defined gene is up 
regulated by specific proteins known as transcription factor that are found 
in families with AAAs. Targeted therapies aiming to avoid transactivation 
of such factors are still in the early stages but their inhibition could 
contribute to complete resolution of the inflammatory and matrix 
degradation associated with AAA expansion (Epstein, 1996) (Table 1.4).  
 
Mechanism & Hemodynamics of Rupture 
In general, it is accepted that the natural history of AAA is further growth 
and eventual rupture. This might have direct correlation to the aneurysm 
diameter. The expansion rate of an AAA is around 0.2-0.4 cm per annum 
(Brady, 2004; Mofidi, 2007). This remains subjective to the individual risk 
factors and genetic predisposition explained in detail in this section of the 
introduction. In theory, the “Laplace law” has been traditionally used to 
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demonstrate why an AAA deforms and ruptures (Hademenos, 1994). 
According to this law there is a direct correlation between tension, 
pressure and the radius of each cylindrical structure. This aids in 
calculating the circumferential tension and the possibility of the rupture 
(Hademenos, 1994). However, this law might not be applicable to infra-
renal AAAs of all shapes (Saccular versus Fusiform) as they might 
present more of a spherical structure than cylindrical in practice. In such 
cases “vessel wall stress” defined as the restoring force per unit area in 
circumferential and longitudinal direction is more useful in defining the 
rupture (Table 1.2). Glagov (1983) demonstrated a linear relationship 
between the thickness of the aorta (tunica media) and that of the aortic 
radius at a mean given blood pressure. So a larger aorta that has a 
thicker wall is more resistant to rupture than a smaller aorta. Therefore, if 
two aortas of unequal size develop an aneurysm of a same size, the 
aneurysm formed from a smaller aorta is at higher risk of rupture. This 
theory was reinforced by the work of Stringfellow (1987). In this study, 
they exhibited that the gradient wall stress in a six (6) cm aneurysm 
arising from three (3) cm and of one (1) cm aortas exhibit significant 
differences in longitudinal and circumferential directions. Therefore, a 6cm 
aneurysm arising from a 1cm native aorta has much higher chance of 
rupture than that of a 3 cm native aorta due to significant gradient wall 
stress differences. Overall, the evidence suggests that the path of rupture 
is multifactorial and its exact nature remains elusive to this date.  
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1.1 Presentation of Rupture 
According to the words of Sir William Osler “Aneurysm of the abdominal 
aorta is very often diagnosed when not present, and when present the 
symptoms may be so obscure that the nature of the trouble is overlooked” 
(Osler, 1905). This perhaps remains the best explanation of AAA and its 
clinical manifestation despite significant advancements in the field of 
diagnostic medicine (Table 1.5). 
 
Table 1.5 Common & uncommon presentation of ruptured AAA. 
 
 
 
Common presentation of ruptured AAA (25-50%)  
(Classic Triad) 
• Sudden onset sever back pain (± abdominal pain) 
• Hypotension (± syncope) 
• Pulsatile abdominal mass  
Non-common presentation of ruptured AAA (30%) 
• Right flank pain. 
• Groin pain. 
• Testicular pain or pressure. 
• Compression effect causing transient lower limb paralysis. 
• Testicular ecchymosis (blue scrotum sign of Bryant). 
• Hernia. 
• Urolithiasis. 
Rare presentation of rupture AAA (5%). 
• Aortocaval fistula (high output cardiac failure, dyspnea, tachycardia, 
wide pulse pressure, cyanosis, and lower limb edema) 
• Aortoenteric fistula (Sever Melena and death). 
• Aorto-left renal vein fistula (abdominal pain, haematuria, silent left 
kidney syndrome). 
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Almost all patients with infra-renal AAA are asymptomatic and their 
diagnosis is mainly incidental. This is mainly the result of an ongoing 
investigation for other abdominal presentation where an ultrasound (USS) 
or computed tomography scan (CT) and detail clinical examination 
reveals a pulsatile mass. AAA becomes symptomatic when they rupture 
or cause complications (Assar, 2009). The most common presentation of 
ruptured infra-renal AAA is the classical triad of:  sudden and severe back 
pain with or without abdominal pain, hypotension and/or syncope and 
pulsatile abdominal mass. However, such presentation is only seen in 25-
50 % of the population and some may present in an entirely different way 
(Table 1.5), misleading clinicians towards other pathophysiological 
conditions (Fielding, 1981). It appears that the anatomical site of AAA 
rupture dictates its clinician presentation and this factor perhaps explain 
why there is 30% misdiagnosis in practice (Marston, 1992). 
 
1.2 Rupture Site & Their Clinical Manifestation 
Given the anatomical location of the abdominal aorta rupture, can occur 
anteriorly (peritoneal), posteriorly (retroperitoneal) or in to the adjacent 
anatomical structure such as bowel (Duodenum, Aorto-enteric fistula), 
Inferior vena cava (aorto-caval fistula), left renal vein (Aorto –left renal 
vein fistula) and in very rare cases contained chronic rupture.  The 
retroperitoneal rupture (posterior) is the most common type of rupture 
(80%) (Rutherford, 1989). This is the result of a tear in the abdominal 
aortic wall that permits blood leak into the posterior compartment of 
abdominal cavity. This manifest itself clinically with the classical triad of 
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presentation as described earlier. Such patients, due to temporary sealing 
of the rupture site due to tamponade effect, may be stable for the few 
hours of presentation and normally have better prognosis due to their 
early diagnosis (Rutherford, 1989). 
 
In 15% to 20% of the cases, the AAA ruptures anteriorly and into the 
peritoneum. In such circumstances, given the amount of free 
embryological space in the anterior compartment of abdominal cavity, the 
extent of bleeding is so severe that patient goes into sudden syncope and 
loses consciousness. Due to the lack of tamponade effect and loss of 
entire circulatory volume, patients do not make it to the hospital (Brewster, 
2003). In very rare scenarios (3-4%), the presence of AAA and constant 
chronic inflammation can cause erosion into the neighboring anatomical 
structures. 
Amongst them, erosion to the inferior vena cava (aorto-caval) remains the 
most common of all. Given the containment of the circulatory volume 
(blood) in such circumstance, the size of the fistula (communication) 
between the aorta and inferior vena cava dictates the presenting 
symptoms. Abdominal bruit on auscultation remains the most common 
clinical finding but in extreme clinical situations, high output cardiac failure 
(dyspnea, tachycardia, wide pulse pressure, cyanosis) and lower limb 
edema or pulsation has also been reported. The Majority of aortocaval 
fistulas are detected during elective surgery (50-90%) and they rarely 
present in extrermis (Davis, 1998; Iriz, 2006).  
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Aorto-left renal fistula remains a rare identity and following its first 
description by Lord et al. and its repair by DeBakey (1958) only 26 
reported cases have been identified in the literature. In the majority of 
cases, the AAA erodes to the left renal vein, which runs anteriorly (90%) 
and in rare anatomical variation posteriorly (1-4%). Almost all patients, 
present with abdominal pain, hematuria and silent left kidney syndrome 
and in rare scenarios, high output cardiac failure (Debakey, 1958). 
 
Due to the close proximity of third and fourth parts of duodenum to AAA, 
in extremely rare circumstances (0.5–2.3%) an aortoeneteric fistula is 
formed. This condition is fatal (95%) and very few patients make it to the 
hospital. The reported incidence of aortoeneteric fistula in general 
population as a result of AAA is 0.04–0.07% at autopsy (Assar, 2009).  
 
In very rare clinical (4%) situations following posterior rupture of AAA, a 
large hematoma and its binding resistance due to peri-aortic tissue (tunica 
adventitia) can result in contained ruptured or sealed ruptured aneurysm. 
Some patients might escape detection for days and months due to their 
limiting clinical manifestation. This was first reported by Szilagyi (1961) 
and the majority of such patients presented with chronic pain and signs of 
compression (transient neuropathy). Such patients may rupture at any 
time and upon their detection, they should be prioritised like ruptured AAA 
cohort (Sazilagyi, 1961).   
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1.3 Surveillance & Screening 
 
The role of a regular screening programme for AAAs has gained 
significant attention in the last decade. The rational is early detection of 
AAA in order is to avoid high mortality and morbidity from rupture. 
According to Cochrane review the odds ratio in favor of screening for 
male population in reduction of mortality was 0.60 (95%CI 0.47-0.78) 
(Cosford, 2007). This review recommends men aged between 65-79 will 
benefit significantly from routine screening for the detection of AAA. The 
method of screening is through ultrasonography and calculation of the 
aorta and/or AAA through Anterior-posterior measurement rather than 
transverse. The use of ultrasound is cheap and none invasive with no 
radiation and a minimal learning curve (Cosford, 2007). The Cochrane 
review did not report any reduction in mortality and morbidity associated 
with the use of routine screening for the detection of AAA in female 
population (OR 1.99; 95% CI 0.36 to 10.88) (Cosford, 2007). Once an 
abdominal aorta of >3 cm in size (termed as abdominal aortic aneurysm) 
is detected, the patient is than followed up by routine surveillance in 
specialized vascular and/or cardiovascular units. For AAA measuring 3-4 
cm in size 12-24 monthly, for 4-4.5 cm AAA 12 monthly and above 4.6 cm 
6 monthly surveillance is recommended (MASS, 2007) (Table 1.6).    
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 Figure 1.1 Algorithm
ic approach to AA
A m
anagem
ent. 
             
Abdominal aortic 
aneurysm (AAA) 
AAA> 5.5 cm 
AAA<5.5 cm 
Ruptured AAA 
Surveillance with 
(Duplex and/or CTA) 
and/or MRA) 
3-4cm AAA requires 24 
months follow up. 
 
4-4.5 cm AAA requires 
12 monthly follow up. 
 
4.5-5 cm requires 6 
monthly follow up. 
 
>5 cm requires 3 
monthly follow up. 
 
 
Repair of AAA  
AAA reaches 5.5 
cm  
If not fit for surgery than conservative and palliative 
in ruptured cases.  
If AAA remains < 5.5cm 
Type of repair  
1). Open repair. 
2). Laparoscopic repair  
3. Endovascular aneurysm 
repair (EVAR): 
a). Custom  
b). Standard  
Patient fit for surgery  
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Preoperative Investigations 
 
1.1 Imaging modality 
Upon suspicion of ruptured AAA, the only treatment is the repair of 
abdominal aortic aneurysm. However, prior to surgery, if the patient is 
stable, the gold standard investigative modality of the choice is computed 
tomography angiography (CTA) (Fitzgerald, 1996). This modality 
demonstrates, the size, shape, site, extent and possible other variations 
or complications of the ruptured AAA with 95 % specificity and sensitivity. 
In addition, CTA can also assist the operating surgeon in minimizing the 
amount of dissection and define an appropriate surgical approach.  In 
unstable individuals an ultrasound abdomen (Kuhn, 2000) can be 
performed to confirm diagnosis although the information obtained from 
this modality is not as precise and informative as CTA. This is mainly due 
to the patient’s body habitus, bowel shadow and its intolerance by 
patients.  In such circumstances, where time is of essence given the 
significant hemodynamic instability, no investigative modality should delay 
surgery (Table 1.6).   
 
1.2 Other investigations 
Once decision for surgery is made, all patients required detailed blood 
evaluation although these investigations should not delay surgery and 
must be parallel to final preparation for surgery. Full blood count (FBC), 
coagulation profile, renal function test, group and save and cross match 
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for blood and its component transfusion are of vital importance (Table 
1.6). 
 
Table 1.6 Investigative Modality & Their Relevance for rAAA. 
 
 
Resuscitation Strategies  
 
The management of a patient with rAAA (hemorrhagic shock) in the 
preoperative period plays a vital role in the final outcome of the patient. 
The ongoing loss in the circulatory volume (blood) causes compensatory 
and reduced perfusion to the vital organs. This explains why such patient 
present with syncope or loss of consciousness. In order to achieve 
adequate perfusion, the aim of resuscitation is to obtain a systolic blood 
Type of investigation Information obtained 
• Computed tomography 
angiogram (CTA). 
 
• Ultrasonography (USS). 
 
• Full blood count (FBC). 
 
 
 
• Renal Function Test (RFTs). 
 
 
 
 
• Coagulation Profile.                 
 
 
 
• Group, Save and cross match  
 
Size, Site, Shape, Anatomy, 
rupture site, defining surgical 
approach. 
 
Site, Size, Shape, Anatomy, No 
detail on site of rupture.  
 
Degree of blood loss 
(Hemoglobin). 
Platelet count, Inflammatory 
markers.  
 
 
Electrolytes (Sodium & 
Potassium), Kidney function 
status (Urea, Cr). 
 
 
 
Activated Partial Thromboplastin 
Time (APTT), Prothrombin Time 
(PT) & international normalized 
ratio (INR). 
 
 
 
Type and rhesus status of patient 
blood for blood and blood 
component transfusion. 
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pressure of 100 mmHg. This is referred to as “permissive arterial 
hypotension” (Hamilton, 2014) and remains the main strategy in the 
primary resuscitation of all types of ruptured aneurysms in the body. In 
permissive hypotension, the objective is to gain adequate perfusion to all 
vital organs but not to increase the systolic pressure to a level that can 
result in further tearing of a rAAA and loss of present tamponade effect 
(Hamilton, 2014).  
 
1.1 Traditional & Current Transfusion Strategies  
 
The optimal transfusion strategy for rAAA has been subject to various 
debates in the last two decades. This debate has resulted in a significant 
shift in the transfusion protocols deployed in the resuscitation of 
hemorrhagic shock patients. The traditional resuscitation strategy was set 
to optimize the cardiac cycle and oxygen delivery system with active fluid 
resuscitation (non-blood components). In this process patients were 
massively transfused with colloid and crystalloid fluids intravenously. 
However, such protocols did not reduce the significant and ongoing 
mortality, therefore a new investigation into the best resuscitation protocol 
was initiated. The outcome of these investigations, demonstrated that 
patients with hemorrhagic shock do not die of inadequate cardiac cycle 
and oxygen delivery. The mortality was mainly due to ongoing 
hemorrhage secondary to coagulopathy disorders despite surgical 
management of the bleeding point (Duchesne, 2008). 
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The outcome of these investigations revealed that coagulopathy starts 
immediately at the time of the trauma and not what was originally believed 
to be several hours later. It has also been established that non-blood 
component (crystalloids/colloid) transfusion worsens the coagulopathy 
furthermore significantly increasing the mortality. In addition, recent 
research suggests that hemorrhagic shock activates anticoagulant protein 
C as a result of inadequate tissue perfusion and not from consumption of 
coagulation factors (Tieu, 2007). Hemorrhagic shock also results in 
hypothermia and subsequent acidosis. Therefore, the new resuscitation 
strategy is aimed at correction of the trauma triad of hypothermia, acidosis 
and coagulopathy with active blood and blood component transfusion 
(Brohi, 2003). However, these studies are not free of methodological 
limitations (e.g. survival bias, heterogeneity) and their application in the 
resuscitation of all types of haemorrhage, including those with ruptured 
abdominal aortic aneurysm, is not currently supported by the literature 
(Hunt, 2014). 
 
Furthermore, individuals with ruptured abdominal aortic aneurysm (rAAA) 
have a number of demographical differences. Patients are much older, 
suffer with more comorbidities and are exposed to a different mechanism 
and type of volume depletion. In addition, aneurysmal degeneration of the 
aorta is a time dependent process (chronic) and indulges the coagulation 
cascade at various molecular and endothelial levels, which is different to 
the sudden impact of trauma and its implications (Kordzadeh, 2015).  
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Operative Methods 
 
1.1 Open Ruptured Abdominal Aortic Aneurysm Repair  
 
Upon diagnosis of ruptured abdominal aortic aneurysm, the only 
treatment is surgery. Open surgery remains the most common technique 
of repair worldwide, although this technique has been replaced by 
endovascular approach in many specialised units across Europe and 
USA. In open surgery the aorta after a midline laparotomy incision is 
exposed and an infra renal and/or a supra renal aortic clamp is applied. 
This is followed by exposure of the common iliac arteries and application 
of vascular clamps. The aneurysm is longitudinally exposed and opened 
through an arteriotomy incision. Depending on the size of the aorta and 
following the ligation of feeding lumbar arteries, a knitted Dacron graft is 
placed and sutured proximally and distally to the native aorta and 
common iliac vessels. The graft is than wrapped with the aneurysm sac 
and the abdomen is closed in layers (Moll, 2011).   
 
1.2 Endovascular Ruptured Abdominal Aortic Aneurysm Repair 
 
In this technique, patient does not require an open abdomen and the 
aorta and common iliac arteries are approached through bilateral common 
femoral arteriotomies. Upon successful cannulation of the common 
femoral arteries, an aortic occlusive balloon is introduced and the arterial 
flow is proximally inhibited by its inflation. Finally, a main body stent is 
introduced through the groin and the contralateral limb is deployed in the 
main endovascular stent from the ipsilateral common femoral artery. This 
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is followed by an on table angiography and closure of the vessels (Moll, 
2007).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29  
CHAPTER 2 
 
Methodology of Thesis  
 
 
2.1 Objectives   
 
As highlighted in the resuscitation section of chapter one, the current 
massive transfusion protocol deployed for hemostatic resuscitation of 
hemorrhagic shock (derived from military and trauma cohort of patients) 
(Brohi, 2007; Henrikson, 2012) assumes that all patients with any type of 
hemorrhage are in coagulopathy. However, the search of literature does 
not demonstrate any evidence to support this protocol in ruptured 
abdominal aortic aneurysms. Therefore, the aim of this thesis is to 
ascertain for the first time:  
1). What is the true coagulation status of infra-renal ruptured abdominal 
aortic aneurysms presenting to our unit? 
2). What is the true coagulation status of infra-renal ruptured abdominal 
aortic aneurysms across the literature? 
3). What is the clinical impact/s (mortality and morbidity) of current 
massive transfusion protocol in hemostatic resuscitation of infra-renal 
ruptured abdominal aortic aneurysms? 
4). What is the best transfusion practice in such group of patients? 
5). Are there any predictors (blood and blood components) of mortality 
and morbidity? 
6). Does such practice have any effect on the overall correction of 
coagulopathy if any?  
7). What is the best practice and probable future recommendations? 
 30  
 
2.2 Ethical Approval  
For the comprehensive, systematic review, Meta-analyses and/or Meta-
aggregation of the literature, no ethical approval was required. In all 
original studies requiring patient data, ethical approval was obtained from 
Mid Essex Hospital services NHS Trust, Broomfield hospital (Audit and 
research committee) prior to the start of the thesis with clinical audit (CA) 
number: CA 13-226 on 08/01/2014 (Appendix 1). 
All the studies were performed in accordance with the declaration of 
Helsinki without disclosing any patient identification.  In all studies no 
individual was subjected to any new and/or alternative 
treatment/intervention and meticulous attention was paid to keep the data 
anonymous and in accordance with the data protection act.  
 
2.3 Methods & Materials 
Data on patients with ruptured abdominal aortic aneurysm presenting to 
Broomfield hospital, Mid Essex Hospital Services NHS Trust was obtained 
from four different local sources, to assure data precision by myself. 
These were as following: 
1). Patients records (notes).  
2). Operative theatre records and data log. 
3). Anesthetic data log  
4). Blood transfusion services.  
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The data was retrospectively collated from the time of ethical approval 
(08/01/2014) to November 2007 (to the point of availability of the data) 
and prospectively to the end of June 2015. 
 
This produced a total of ninety individuals (n=90). Complete data was 
available only for eighty-two (n=82) individuals. The lack of complete data 
for the remaining eight patients (n=8) was mainly due to inadequate data 
records from 2007 to 2008 and lack of centralization of anesthetic log and 
patient’s records.  
 
2.4 Data Collection 
The following data (variables) were recorded into the excel sheet with pre-
defined coding system for later statistical analysis: 
1). Patient demographics (age, gender). 
2). Patients comorbidities (chronic obstructive pulmonary disease, 
Smoking, Hypertension, history of previous coagulation disorder).  
3). American society of anesthesiology score (ASA). 
4). Initial emergency services presenting hematological markers 
(Hemoglobin, Neutrophil, Lymphocyte, Neutrophil lymphocyte ration 
(NLR). 
5). Initial emergency department presenting coagulation status (Platelet 
count, international normalized ratio (INR), Prothrombin time (PT) and 
activated partial thromboplastin time (aPTT). 
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6). Operative data (type of operation, method of operation, cross clamp 
time, aneurysm size, type of conduit (prosthetic graft), suture material and 
size, blood loss) 
7). Total Blood component transfusion on each individual (Platelet pool, 
Packed red blood cell, fresh frozen plasma). 
8). Post transfusion coagulation status (Platelet count, international 
normalized ratio (INR), Prothrombin time (PT) and activated partial 
thromboplastin time (aPTT). 
9). Duration of intensive care unit and hospital stay (in days), mortality 
and morbidity. 
 
2.5. Data Inclusion  
In order to increase the internal, external validity and robustness of each 
individual study the following inclusion were applied: 
1). Data was extracted only on ruptured infra-renal abdominal aortic 
aneurysm cohort. 
2). No mixed etiology was included (other ruptured aneurysms and/or in 
conjunction with). 
3). Complete availability of all data (variables) on each individual as 
highlighted in section 2.4 of this manuscript.  
4). All patients had confirmed ruptured abdominal aortic aneurysm on 
computed tomography angiography (CTA) and no tender aneurysm (non- 
ruptured but painful) was included.  
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2.6 Definitions 
In order to avoid heterogeneity, create a uniform and replicable approach, 
all terminologies in this thesis were defined according to their respective 
and acceptable international definitions as follow:    
 
1).  Ruptured abdominal aortic aneurysm (rAAA) was defined as any infra 
renal abdominal aortic aneurysm that has lost its wall integrity (breech of 
the vessel) resulting in extravasation of the contrast and/or blood outside 
the aortic wall based on CTA and clinical findings.   
2). All comorbidities were defined in accordance to definitions provided by 
world health organization (WHO). 
3). Coagulopathy was defined Coagulopathy was defined as a condition in 
which clot formation was impaired. Therefore, patients with aPTT >40 
seconds and/or international normalized ratio of >1.2 and/or platelet count 
of <150 10/L9 were deemed coagulopathic in the broader terminology. In 
addition, the following definitions were also applied (Greuters, 2011; Hunt, 
2014):  
• Mild coagulopathy was defined as APTT >40 seconds and/or 
international normalized ratio between 1.2 and 1.5 and/or platelet 
count of 100 ×10/l
9
-150 ×10/l
9
.  
• b. Significant coagulopathy was defined as APTT >40 seconds 
and/or international normalized ratio of more than 1.5 and/or 
platelet of < 100 ×10/l
9. 
4). Disseminated intravascular coagulation is an acquired syndrome 
defined by the intravascular activation of the coagulation cascade with 
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loss of localization arising from different causes.   
5). No robust definition of contained versus free rupture of abdominal 
aortic aneurysm could be identified in the literature.   
6). The study end point was set at 30-days for all outcomes of mortality 
and morbidity. 
7). Morbidity was defined according Clavien-Dindo classification t 3 
(Dindo, 2014) (considered a major complication that requires medical 
and/or surgical intervention).  
8).Morbidity was also recorded in thrombotic and non-thrombotic 
complications ( hyper and/or hypo-coagulate state resulting in arterial 
thrombosis).  
9). Mortality was defined as death from any cause within the duration of 
hospital stay or at 30 days.  
10). All hematological values were recorded in accordance to their 
international and national accepted ranges and values.  
11). All blood and blood component transfusions were recorded in units. 
12). Time duration was calculated in minutes and days for all variables.  
2.7 Coding & Statistical Analysis 
After completion of the data collection by myself, all data was fed into an 
excel sheet (Microsoft office) and coded by myself in accordance with the 
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requirement of statistical package for the social sciences (SPSS) IBM 
version 20.0 (Chicago, IL). A different type of statistical analysis for each 
study was conducted and details of each are highlighted in each chapter 
of this thesis, however certain standards were set for all study design.  
Each study design was set on the background of null hypothesis and this 
was put into detailed assessment. All scale variables were categorized 
according to their median values. All variables that had previously defined 
normal ranges (hemoglobin, platelet count, International normalized ratio 
(INR) Prothrombin time (PT) and activated partial thromboplastin time 
(aPTT), Neutrophil, Lymphocyte) (section 2.6 definitions) were 
categorized to three different groups of normal, low (hypo) and high 
(hyper) Levels. The best cut of value at highest sensitivity and specificity 
at 95 % confidence interval for values with no prior range and 
international value was acquired through area under curve (AUC). Time 
was calculated in minutes and hours and used in a uniform way 
throughout the entire thesis.  
Test of probability was considered significant at p value of <0.05 at 95% 
confidence intervals. Logistic regression analysis (binary) was used to 
determine the association and/or impact of each variable to that of 
predefined outcomes (e.g. mortality and morbidity). Those variables that 
demonstrated a significance with p value <0.1 at univariate logistic 
regression were then entered to the multivariate logistic regression to 
assess and evaluate their independence. Other test of statistics deployed 
in this thesis, were Kruskal- Wallis, Chi-square and Student t-test for 
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assessments of differences across the outcome groups and/or variables. 
The agreement between two independent assessments of ruptured 
abdominal aortic aneurysm measurements (surgeon and radiologist) was 
carried out using Cohen’s k (kappa) coefficient.  The detail of each 
statistical analysis is highlighted in detail in each individual chapter.   
2.8 Systematic review & Meta-Analysis   
Systematic reviews and meta-analyses were performed using 
methodology as described by the Cochrane Collaborative 
(http://www.york.ac.uk/crd/guidance/). Reporting of systematic reviews 
and meta-analyses were carried out using the validated PRISMA 
(Preferred Reporting Items for Systematic Reviews & Meta-Analyses) 
(Appendix 2). 
2.9 Literature Search  
An electronic search of literature was carried out using appropriate 
keywords and/or medical subject headings (MeSH) headings through 
Medline, CINHAL, Scopus, Embase and Cochrane library database. All 
abstracts were retrieved and reviewed. Studies that appeared to fulfil the 
eligibility criteria but had insufficient information in the abstracts were also 
retrieved and examined in full. References within retrieved articles were 
manually searched for further potential studies. 
2.10 Quality Assessment  
All articles were assessed for their validity, bias, applicability, and 
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inference using a critical appraisal tool provided by the Oxford Critical 
Appraisal Skills Programme (CASP) (Appendix 3). The strength of 
evidence and their recommendation for future practice was also assessed 
through the National Institute for Health and Care Excellence (NICE) 
checklist (Appendix 4). 
2.11 Statistical Analysis in Systematic Review 
The pooled analysis for systematic review was conducted by calculation of 
the mean value in addition to pooled prevalence of coagulopathies, and 
95% CI were estimated with a variance weighted random effects model. 
This was done using MedCalc statistical Software version 16.1.  
2.12 Methodological & statistical support 
The entire statistical analysis throughout this thesis was performed by 
myself and reassessed by my clinical supervisor Mr. Yiannis 
Panayiotopoulos whom has published extensively within the field of 
vascular surgery and has been a supervisor of various PhDs in his 
respective field with authorship of a few surgical books. Each individual 
methodology was evaluated and examined in detail for their robustness by 
both respected supervisors prior to their publication and peer review in 
respected medical journals.  
 
 
 
 
 
 
 38  
CHAPTER 3 
 
Baseline Coagulation of Ruptured Abdominal Aortic Aneurysms and 
Their Impact on 30-Day Mortality and Morbidity: A Single Center 
Cohort Study. 
 
3.1 Introduction 
 
For decades, the high mortality of rAAAs has been attributed to 
hemorrhage secondary to coagulopathy. In recent years, there has been a 
decline in the mortality incidence of rAAAs. In the early resuscitation phase 
and context, this decline has been attributed to the better understanding 
and correction of the trauma triad (hypothermia, acidosis and 
coagulopathy) and the advent of new transfusion protocols (Brohi, 2007; 
Henriksson, 2012). Despite such suggestions, emerging evidence 
speculates that unlike traumatic hemorrhagic and subsequent 
coagulopathy, patient with rAAA possess a normal or an activated 
coagulation (Fransson, 2012). Furthermore, active and liberal hemostatic 
resuscitation of rAAA patients with fresh frozen plasma and platelet pool 
(other than packed red blood cells) to correct the initial suspected and 
assumed coagulopathy can contribute to mortality and/or thrombotic 
complications (Fransson, 2012). Hence, it is vital to establish whether such 
patients do present with coagulopathy in the first instance and if so, do they 
require coagulation correction or a minimal transfusion strategy suffice. The 
aim of this study is to establish the baseline coagulation and hematological 
markers of individuals presenting with rAAA to the ED and with a secondary 
aim to assess their impact on the 30-day mortality and morbidity.   
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3.2 Material & Methods 
A retrospective study of n=101 consecutive patients with suspected infra 
renal ruptured abdominal aortic aneurysm (rAAA) from November 2007 to 
June 2015 that presented to the emergency department was conducted. 
Five patients (n=5) were deemed to be for palliation and another five (n=5) 
did not have any preoperative blood assessment. Eight patients (n=8) had 
a mixed picture of abdominal and/or iliac and/or supra renal and/or tender 
aneurysm and were excluded from the study. The remaining individuals 
(n=82) had confirmed clinical and radiological infra-renal AAA rupture. The 
Mid Essex Hospital services NHS Trust, has estimated population 
coverage of 380,000 people. Data on patient demographics (age and 
gender), comorbidities (Hypertension (HTN), Chronic obstructive 
pulmonary disease (COPD), Active smoking,) coagulation profile 
(Prothrombin time (PT), Activated partial thromboplastin time (aPTT), 
International normalized ratio (INR), Haemoglobin (Hb), hematocrit (Ht) and 
platelet count (Plt) were collected. Due to a lack of any new or alternative 
interventions ethical approval was granted from the local hospital with audit 
number CA13-226.  
 
Parameters:  
The computed tomography angiography (CTA) of the entire cohort were 
assessed by two separate investigators (interventional vascular radiologist 
& vascular surgeon) and the aneurysm size was calculated and presented 
in millimetres. The maximum diameter was taken as the true size of the 
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AAA. The agreement level in size measurement was assessed using 
Cohen’s Kappa Coefficient (ĸ=0.82). No patient demonstrated loss of 
consciousness prior to surgery and the Glasgow Coma Scale (GCS) of all 
patients were 15/15. No patient exhibited hypothermia upon arrival to the 
emergency department. None of the patients were on any local (aneurysm) 
screening programme or had any known coagulopathy and/or 
haematological disorders. Eighty individuals (n=80) were already on Aspirin 
75 mgs upon arrival to the emergency department and none were on any 
other antiplatelet or anticoagulants.  All patients had an open repair of the 
ruptured abdominal aortic aneurysm with straight knitted Dacron graft, as 
endovascular option is not routinely available. All patients received 5000 IU 
of heparin upon application of the aortic clamp (infra-renal). 
Definitions  
1. The study endpoint was set at 30 days for all outcomes of mortality. 
The mortality was defined as death from any cause.  
2. Coagulopathy was defined as international normalisation ratio 
(INR)> 1.2 (normal value: 0.9 to 1.2) and platelet count of less than 
150×109/l. (Normal value: 150×109/l to 400150×109/l) (Hunt, 2104).  
3. Significant coagulopathy was defined as Platelet count of < 
100×109/l and INR > 1.5 (Hunt, 2014).  
4. Thrombosis was defined as complications arising from 
thromboembolic phenomenon resulting in blockage of the 
corresponding vessel (Hunt, 2014) 
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5.  Morbidity was defined according to the Clavien-Dindo (2013) 
classification ≥3 (considered a major complication).  
 
Statistical Analysis 
Statistical analyses were undertaken using IBM Statistical Package for the 
Social Sciences (SPSS) version 20.0. Scale variables such as age, 
haemoglobin (Hb), platelet count (Plt), haematocrit (Ht), prothrombin time 
(PT), Activated partial thromboplastin time (aPTT) and international 
normalisation (INR) were categorised according to their respective median 
values. Differences between the two groups (normal coagulation versus 
coagulopathy) were determined using Pearson Chi-Squared tests of a 
difference. A p value of 0.05 or less was deemed to be statistically 
significant.  
 
3.3 Results 
The median age of the cohort was 75 years (range, 51-92) with male 
predominance (male n=66, 85% vs. female n=16, 19.5%, Table 1). The 
median size of rAAA was 75.52 mm (range, 40-100). Pre-existing 
hypertension was found in 60.9%(n=50), chronic obstructive pulmonary 
disease (COPD) in 28 %(n=23), active smokers in 23% (n=19) and acute 
renal failure was noted in three patients (3.9%). The median presenting 
value for Hb was 11.3 mg/dl (Interquartile Range (IQR), 9.45-13.3,) whilst 
the median Hematocrit was 34.0% (IQR, 28.25-39.0%) and the platelet 
count was 176×109/l (IQR, 122×109/l -210×109/l). The median value for PT 
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was 13.1 (IQR, 10.1-35, mean= 14.79), for APTT was 29.55 (IQR 20.4- 
240, mean=34.7) and for INR was 1.12 (IQR, 0.9-2.91, mean= 1.25) (Table 
3.1) (Table 3.2). 
 
Coagulation & Mortality 
According to the defined parameters only 17.1% (n=14/82 vs n=68/82) 
(p<0.001) of the entire cohort was found to have coagulopathy (INR>1.2 
and PLT< 150×109/l). Only one patient was found to have significant 
coagulopathy (INR>1.5 and PLT <100×109/l). Overall, no patient expired 
from hemorrhage  
 
    Non 
Coagulopathic 
Mild 
Coagulopathy 
p= 
    n= % n= % 
Gender Male 54 79.4% 12 85.7% 0.588 
Female 14 20.6% 2 14.3% 
    
     
Age 18-75 years 37 54.4% 5 35.7% 0.202 
>75 years 31 45.6% 9 64.3% 
    
     
ASA Grade 2 15 22.1% 2 14.3% 0.038 
3 25 36.8% 2 14.3% 
4 24 35.3% 6 42.9% 
5 4 5.9% 4 28.6% 
    
     
Hypertension No Hypertension 25 36.8% 7 50.0% 0.355 
Hypertensive 43 63.2% 7 50.0% 
    
     
COPD No COPD 46 67.6% 13 92.9% 0.056 
COPD 22 32.4% 1 7.1% 
    
     
Smoking 
Status 
Non-Smoker 51 75.0% 12 85.7% 0.387 
Smoker 17 25.0% 2 14.3% 
    
     
Hemoglobin 
Pre-Op 
Up to 11.5g/l 35 51.5% 9 64.3% 0.381 
>11.5g/l 33 48.5% 5 35.7% 
Table 3.1 Patient demographics in the normal & coagulopathy group. 
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secondary to coagulopathy and the overall mortality incidence was 14.6% 
(n=12/82), with significant male predominance (n=10/12). The Chi-Square 
test of difference amongst the two groups (normal versus coagulopathy) 
showed no statistically significant difference in demographics, 
comorbidities and the presenting hemoglobin. There was also no 
statistically significant difference (p=0.10) in mortality outcomes associated 
with both groups at 30-days (Table 3.2).  
 
    Number Percentage 
Variables  Parameters  
Age 18-75 years 42 51.2% 
>75 years 40 48.8% 
  
   
Gender Male 66 80.5% 
Female 16 19.5% 
  
   
Hb Up to 11.5g/l 44 53.7% 
>11.5g/l 38 46.3% 
  
   
  
   
Haematocrit Up to 0.3500 45 54.9% 
0.35 37 45.1% 
  
   
APTT Up to 30.00 47 57.3% 
>30.00 35 42.7% 
  
   
PT Up to 13.000 37 45.1% 
>13.000 45 54.9% 
Table 3.2 Hematological markers. 
 
Coagulation & Morbidity  
A total of 22 patients (26.8% of the entire population) experienced morbidity 
within 30-days post rAAA repair. Postoperative thrombotic events 
(thromboembolic phenomenon) occurred in 21.9% (n=18/82) of the entire 
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cohort. Those that lead to mortality were 8.3% (n=7/82) contributing to 
58.5% of the overall mortality (n=7/12). They were due to bowel (n=4) and 
limb ischemia leading to irreversible acidosis (n=3). Other thrombotic 
events were ischemic stroke, Ischemic myocardial infarction, and renal 
artery thrombosis. The overall 30-day thrombotic events in both groups 
(Chi-Square) (normal versus coagulopathy) showed no statistically 
significant difference (p=0.51). Furthermore, thrombosis led mortality could 
not achieve a statistically significant difference in both groups (p=0.67) 
(Table 3.3 & 3.4).   
 
              
    Non 
 Coagulopathic 
Mild  
Coagulopathy 
p= 
    n= % n= % 
Thrombosis 
(30-Day) 
No 
Thrombosis 
54 79.4% 10 71.4% 0.511 
Thrombotic 
event 
14 20.6% 4 28.6% 
    
     
Mortality (30-
day) 
Alive  60 88.2% 10 71.4% 0.105 
Deceased 8 11.8% 4 28.6% 
Table 3.3 30-Day Thrombosis & Mortality Events Post rAAA Repair. 
 
 
 
 
3.4 Discussion 
The outcome of this study demonstrates that individuals with rAAAs do not 
commonly present with coagulopathy to the ED. It appears that a very 
limited number of individuals (n=14, 17.1%) (INR>1.2 and PLT< 150×109/l) 
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show signs of coagulopathy and this may not necessarily require any active 
correction. My finding seems to complement the work of Reed and 
colleague, where no coagulopathy in rAAAs on their initial presentation to 
the ED was detected (Reed, 2013).  
In recent years, there has been a significant emphasis on early haemostatic 
resuscitation and coagulation correction of haemorrhagic shock. These 
suggestions and /or guidelines are mainly from research, derived from 
military and civilian trauma (Graham, 2012). In fact, no evidence in the 
literature could support the active and liberal use of fresh frozen plasma 
and platelet pool in the early resuscitation phase of rAAAs.  Furthermore, 
emerging evidence suggests that patients with rAAA may be in a pro-
coagulant state and might not have the same pathophysiological alterations 
that are witnessed in haemorrhagic shock following trauma (Mantovani, 
1997). 
 
 
              
    Non  
Coagulopathic 
Mild 
Coagulopathy 
  
    n= % n= % p= 
Thrombosis 
(30-Day) 
No Thrombosis 3 37.5% 2 50.0% 0.679 
Thrombotic 
event 
5 62.5% 2 50.0% 
Table 3.4 Rates of Thrombotic Events in Patients Who Died Within 30-Days Of 
rAAA Repair. 
 
 
The first major difference (rAAAs vs Trauma) is related to the time 
dependent and chronic process of aneurysm formation. During this stage, 
 46  
injury to the endothelium acts as a nidus for the adhesion, migration of 
platelets and the generation of fibrin. The release of von Willbrand Factor 
(vWF) and other hematological factors over months and/or years promote 
the activation of tissue factor (TF) that generates thrombin formation 
through factors X and VII (Edington, 1991). In addition, the size of mural 
thrombus exhibits a direct (positive) correlation to the aneurysm size and 
its anatomical tortuosity (Yamazumi, 1998; Adam, 1999), thus, indicating 
an ongoing active coagulation cascade. Furthermore, in a study by Adam 
et al. even non-ruptured AAAs exhibited significant coagulation differences 
to that of rAAAs. The authors demonstrated that AAA individuals are more 
pro-coagulant once they rupture and such a pro-coagulant state persists 
throughout the duration of the operation and resolves in the postoperative 
period (≥ 24 hours) (Roberts, 2006). 
Secondly, the initial resuscitation strategy commonly adopted in rAAA 
patients is “permissive hypotension” (Illig, 1997). Such hypotension may 
well result in hypo-perfusion and early coagulopathy, but unlike trauma 
patients, evidence in the rAAA cohort demonstrates no significant 
relationship between hypotension and/or hypo-perfusion, the degree of 
coagulopathy and fibrinolytic parameters. In addition, there are suggestions 
that the elevation of fibrinolytic factors is related to the application of supra-
celiac cross clamp during surgery and not on the initial presentation of the 
patients to the ED (Packman, 1994; Gertler, 1996). 
In this study, thrombotic complications contributed to more than half of the 
30-day mortalities (n=7/12, 58%). Platelets have a significant and potent 
role in thrombosis. Their adhesion to sub-endothelium of the vasculature 
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forms thromboxane A2 and results in the secretion of platelet granules 
accelerating platelet aggregation and thrombin generation (Sakgius, 2007). 
The study by Skagius et al. (2008) demonstrated that rAAAs possess a 
higher thrombin-antithrombin, prothrombin fragment, von Wilbrand factor 
antigen and D-dimers in comparison to non-ruptured aneurysm, indicating 
an active coagulation cascade (Tamyraja, 2008). Therefore, liberal and 
proactive haemostatic resuscitation (platelet pool and Fresh frozen plasma) 
could increase thrombotic complications even further.  
The outcome of this study demonstrates that the application of the new 
haemostatic resuscitation (strategies) derived from military and civilian 
trauma such as the active transfusion of platelet pool and fresh frozen 
plasma in addition to the required red blood cells in the ED might not be 
necessarily applicable to the rAAAs.  This is based on the evidence that 
rAAAs do not present with coagulopathy and/or hypothermia noticed in the 
trauma individuals. In addition, hypotension in rAAAs does not necessarily 
result in hypo perfusion. Therefore, refinement of transfusion protocols in 
light of emerging evidence for the active resuscitation of rAAAs is highly 
advocated. This study does not challenge the transfusion of red blood cells 
in individuals with haemorrhagic shock secondary to rAAAs but does call 
into question the active transfusion of other products such as platelet and 
fresh frozen plasma in the early resuscitation phase.       
This study inherits the weakness of being retrospective in nature and a 
higher number of individuals in a randomized controlled trial and/or 
comparative study would have been optimal. However, given the nature of 
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rAAAs, their associated high morbidity and mortality, such methodology 
might not be feasible and current practice may have to rely on observational 
studies. Furthermore, the assessment of other variables or the deployment 
of various scoring systems such as Glasgow Aneurysm Score (GAS), 
Hardman Index (HI), Edinburgh ruptured Aneurysm Score (ERAS) and 
Physiological and Operative Severity Score for the enUmeration of 
Mortality and Morbidity (POSSUM) have failed to predict survival in rAAAs 
and cannot be used as reliable markers (Gatt, 2009).  
 
3.5 Conclusion 
Patients with ruptured abdominal aortic aneurysms do not present to the 
ED with coagulopathy and if they do, the coagulopathy is often mild and 
does not require correction. The presence or the lack of coagulopathy does 
not have any impact on thrombotic induced morbidity or peri-operative (30-
day) mortality. Ruptured abdominal aortic aneurysms exhibit different 
baseline coagulation to those of trauma and further research in this area is 
advocated. In next chapter, the finding from our unit will be assessed and 
evaluated in contrast to what is known in the literature with regards to the 
coagulation status of ruptured abdominal aortic aneurysms.  
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CHAPTER 4 
 
Presenting Baseline Coagulation of Infra Renal Ruptured Abdominal 
Aortic Aneurysm: A Systematic Review and Pooled Analysis. 
 
 
 
4.1 Introduction 
 
The lack of high quality evidence regarding the coagulation status of 
patients with rAAAs has led to speculations, reliance on anecdotal 
experience and suggestions about their appropriate haemostatic 
resuscitation. Furthermore, individuals with ruptured abdominal aortic 
aneurysm (rAAA) have a number of demographical differences. Patients 
are much older, suffer with more comorbidities and are exposed to a 
different mechanism and type of volume depletion. In addition, 
aneurysmal degeneration of the aorta is a time dependent process 
(chronic) and indulges the coagulation cascade at various molecular and 
endothelial levels, which is variant to the sudden impact of trauma and its 
implications (Kordzadeh, 2015).  
In order to optimise patient care, diminish disparities and objectify the 
current protocols, the first systematic review of the literature was 
performed to establish the baseline coagulation status of infra renal 
ruptured abdominal aortic aneurysms. In this review I did not settle with 
the term “coagulopathy” alone and investigated their subtypes in detail 
(mild versus significant) against the defined standards and definitions 
provided by the literature. 
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4.2 Material & Methods: 
 
 
Search Strategy  
 
A systematic search of the literature from 1966 to July 2015 was 
conducted in Medline, CINHAL, Scopus Embase and Cochrane library. 
The following keywords and/or medical subject headings (MeSH) were 
used: “ruptured abdominal aortic aneurysm” and/or “ruptured infra renal 
abdominal aortic aneurysm” and/or “coagulation” and/or “coagulopathy”. 
The search was performed in accordance to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
(Moher, 2009). Bibliographies of the retrieved articles were also manually 
checked for any additional studies not identified in the primary search. All 
abstract was retrieved and reviewed. Studies that appeared to fulfil the 
eligibility criteria but had insufficient information in the abstract were also 
retrieved and examined in full. 
Results 
The electronic search returned a total of 71 studies (Figure 4.1) (Moher, 
2009). A further manual search revealed 2 more articles. Of the total 73 
studies, 12 articles were found to be duplicates leading to 61 articles in 
total. The abstracts of these articles were screened and 30 studies were 
further (language restriction n=7 and non-relevant n=23) excluded. The 
full texts of 31 studies were assessed for eligibility and of these 24 were 
excluded against the inclusion criterion. A total of seven studies (Table 
4.1) were included in this systematic review.  
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Exclusion Criteria   
 
The following articles were excluded: 
1). Non-human and non-adult studies. 
2). Abstracts and conference proceedings. 
3). Case reports, narrative reviews, commentary and opinions. 
4). Other studies that did not report the outcomes of coagulation/coagulopathy 
or investigated coagulopathy only post rAAA repair. 
5). Articles that were not in English language.  
 
Quality Assessment & statistical analysis  
  
In order to achieve an informed conclusion and an evidence base approach 
the included articles were assessed for their validity, bias, applicability and 
inference through critical appraisal tool provided by Oxford critical appraisal 
skills Programme (CASP, 2015). Due to lack of consistency and uniformity of 
the provided data, as well as heterogeneity in the population across the 
studies, a meaningful statistical analysis (meta-analysis) was not deemed 
plausible. However, the data was presented in a tabulated format and a 
pooled analysis was performed. Data extraction included the type of the 
studies, number of recruited individuals, coagulation factors, outcome, and 
conclusion. The strength of evidence and their recommendation for future 
practice was also assessed through National Institute for health and Care 
Excellence (NICE) checklist (Weightman, 2015). In addition, 
recommendations for future research were formulated based on the current 
systematic review outcome.   
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Standards & Definitions  
 
In order to avoid heterogeneity and create a uniform approach, all terms were 
defined according to their respective and acceptable definitions (Greuters, 
2011; Hunt, 2014).   
 
 
1. Coagulopathy was defined as a condition in which clot formation was 
impaired. Therefore, patients with aPTT > 40 seconds and/or 
international normalized ratio of more than 1.2 and/or platelet count of 
< 150 ×10/l9 were deemed coagluopathic in the broader terminology. In 
addition, the following definitions were also applied:  
 
a. Mild coagulopathy was defined as APTT > 40 seconds and/or 
international normalized ratio between 1.2-1.5 and/or platelet count 
of 100×10/l 9-150 ×10/l 9. 
b. Significant coagulopathy was defined as APTT > 40 seconds and/or 
international normalized ratio of more than 1.5 and/or platelet count 
of < 100 ×10/l 9. 
 
2. Disseminated intravascular coagulation (DIC) was defined as an 
acquired syndrome defined by the intravascular activation of the 
coagulation cascade with loss of localization arising from different 
causes.  
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Table 4.1 Inform
ation obtained from
 the recruited studies (n=7) referring to type, size, coagulation factors and outcom
e. 
  
  
Study/  
Population 
A
ssessed 
Factors 
O
utcom
e 
C
onclusion  
M
ontan et 
al. 
2015.  
R
etrospective 
C
ohort. 
N
= 91 
 
1.H
em
oglobin. 
2.P
latelet count.  
3.International norm
alization ratio.  
4.Activated partial throm
boplastin tim
e. 
5.Fibrinogen. 
6.P
rothrom
bin ratio. 
• 
P
latelet &
 Fibrinogen show
 linear relationship to blood 
pressure (70m
m
H
g).   
• 
H
ypotension results in low
 Fibrinogen Level (<1.5) 
(p=0.001). 
• 
Low
 Fibrinogen Level is associated w
ith 10 fold increase 
in intraoperative bleed  > 2 liters (p=0.009). 
N
o significant 
coagulopathy. 
 S
hock results 
in coagulopathy. 
R
eed et al. 
2013.  
R
etrospective 
cohort. 
N
= 119 
 
1.H
em
oglobin. 
2.P
latelet count.  
3.International norm
alization ratio.  
4.Activated partial throm
boplastin tim
e. 
5.prothrom
bin tim
e. 
• 
14.3%
 had IN
R
 ≥1.5. 
• 
9.2 %
 had platelet < 100 ×10
9/l. 
• 
AP
TT (p=0.353) w
as not significant. 
• 
P
T (p =0.25) w
as not significant. 
 
N
o significant 
coagulopathy. 
Fransson 
et al. 
2012.  
R
etrospective 
cohort. 
N
=55 
 
1.P
latelet count.  
2.International norm
alization ratio.  
3.Activated partial throm
boplastin tim
e. 
4.A
cidosis ≥ 6m
m
ol.  
• 
12.7 %
 had IN
R
 ≥1.5. 
• 
N
=2 had D
IC
. 
• 
H
igh incidences of throm
botic m
ortality. 
 
N
o significant 
coagulopathy/ 
activated 
coagulation. 
Fujita et 
al. 
2012.  
R
etrospective 
cohort. 
N
=64  
 
1.H
em
oglobin. 
2.P
latelet count.  
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Figure 4.1 PRISMA-Flow Chart 
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The total population across these seven studies was 461 patients. These 
patients all presented with rAAA and were subjected to coagulation 
assessment of: 1). Platelet count. 2). International normalized ratio (INR). 3). 
Activated partial thromboplastin time (aPTT). 4). Fibrinogen and 5). D-dimer 
or fibrin degradation product (FDP) prior to surgery to establish their 
coagulation baseline (coagulopathy versus none). This included six (n=6) 
retrospective cohort and one comparative study (n=1). No randomized clinical 
trial (RCT), systematic review and/or meta-analysis were identified.  
 
Study Quality 
 
Of the seven included studies, three studies scored maximum marks (8/8) 
according to the CASP checklist (Skagius, 2008; Fransson, 2012; Montan, 
2015). Two studies scored 7/8 (Davies, 1993; Fujita, 2012) and the remaining 
two studies (Getaz, 1997; Reed, 2013) scored 6/8 (Table 4.2). The strength 
and grade of each study were also measured against (NICE) checklist.  
 
Normal Coagulation vs. Coagulopathy  
 
All of the seven studies (n=7) with 461 patients had assessed the range of 
platelet count in detail. Pooled analyses of these studies demonstrated 86.3% 
(n=398) of the population to have a platelet count of >150×10/l 9. Only 
12.1%(n=56) had a platelet count of <150×10/l 9. Data on the platelet counts 
of seven patients were unavailable (n=7/461). Data on coagulation status 
using international normalized ratio (INR) was available on 363 patients. 
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Within this group, 84.8% (n=308/363) had an INR <1.2 whilst 15.1% 
(n=55/363) had INR>1.2. The activated partial thromboplastin time (aPTT) 
was available and measured in 396 patients. The aPTT was less than 40 
second in 86.2% (n=340/396) of the cohort and more than 40 seconds 13.7% 
(n=54) (Table 3) (Figure 4.2).  
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Figure 4.2 Chart demonstrating the comparison between two groups of patients with no 
coagulopathy versus coagulopathy 
 
 
Mild Versus Significant Coagulopathy 
Sub-group analysis was performed to establish the severity of the 
coagulopathy. Further examination of 56 patients (12.1% of the overall 
population) with the coagulopathy, demonstrated that more than half of the 
individuals (n=31/56, 6.69%) had a platelet count range between 100-
150×10/l9. The remaining 25 patients (n=25/56, 5.4%) had a platelet count of 
less than 100×10/l9.  Amongst 55 individuals (15.1%) that had INR >1.2, 6 % 
(n=22/55) had an INR range between1.2 to 1.5. The remaining 9% (n=33/55) 
had an INR> 1.5. The activated partial thromboplastin time was more than 40 
seconds in 13.7% (n=54) of the entire cohort (n= 396) (Table 4.4) (Figure 4.3). 
 
Fibrinogen, D-Dimer & DIC 
Only three studies (n=3) with population of 165 patients, reported the serum 
levels of Fibrinogen (normal range, 150-400 mg/dL). Four individuals (2.4%) 
reportedly had a high levels of fibrinogen > 400md/dL and one individual had 
(0.6%) fibrinogen of less than 150 md/dL. Overall 97% of patients had normal 
86.3%
12.1%
84.8%
15.1%
86.2%
13.7%
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No coagulopathy versus coaguloptahy 
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Fibrinogen levels. The D-dimer or fibrin degradation product (FDP) was 
reported in two articles with population of 119 and it was significantly elevated 
in 46.2% (n=55) of the individuals. Only 4 (2.4%) individual in the entire cohort 
demonstrated DIC.  
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Figure 4.3 Chart demonstrating the comparison between the sub-types of 
coagulopathy (mild versus significant). 
 
4.3 Discussion 
 
Pooled analysis of the included studies in this review suggests that the 
majority (85%) of ruptured abdominal aortic aneurysms (rAAA) do not present 
with coagulopathy to the emergency services. Amongst the individuals that 
do, significant coagulopathy is limited to only 6% and disseminated 
intravascular coagulation (DIC) to 2.4% of the entire population. Furthermore, 
fibrinogen serum concentration was normal in 97% (n=165) and the D-dimer 
or fibrin degradation product (FDP) level was elevated in 46.2% (n=55/119) of 
the cohort.  These findings appear to be in conflict with earlier assumptions 
about the baseline coagulation (and assumed coagulopathy) of rAAAs. This 
review questions the current and the ongoing comparison of rAAAs to that of 
traumatic (civilian and military) hemorrhage induced coagulopathy in the 
literature (Mell, 2010; Kauvar, 2012). This conflict could be explained by the 
presence and/or lack of certain variables and/or pathophysiological processes 
and postulations.  
 
6.70% 5.42% 6% 9%
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Mild versus Significant Coagulopathy 
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Firstly, in the study by Montan et al. (2015) a sub-group analysis, found a 
linear relationship between the preoperative presenting blood pressure, 
platelet count and the fibrinogen concentration levels. A cut-off blood pressure 
value of ≤ 70 mmHg was found to have a positive linear relationship to low 
serum levels of fibrinogen < 150md/dL (p=0.001) (normal range, 150-400 
mg/dL) and reduction of circulatory platelet count  (<150×10/l 9) (p=0.05). 
Therefore, it appears prior evidence relating coagulopathy to that of 
hypotension is attested but there appears to be a further cut-off in the blood 
pressure measurements (≤ 70 mmHg) beyond which significant coagulopathy 
starts to occur in rAAAs. Given fibrinogen concentration is first to fall to a 
critically low level in major hemorrhage as the part of coagulation cascade 
(Levy, 2014), the presence of normal fibrinogen in the majority of (97%) 
individuals suggest hemodynamic instability may not be as profound as that of 
traumatic hemorrhage. This outcome is also complemented by Al-Barjas et al. 
(2006) study where nine (n=9) rAAAs with no hemodynamic instability 
demonstrated normal fibrinogen levels on their presentation to the hospital.  
Furthermore, randomized placebo-clinical trial (RCT) of Rahe-Meyer et al.  
(2013) demonstrated total avoidance of blood and blood product transfusion 
when fibrinogen concentration versus placebo was within normal limits.       
 
Secondly, there is a clear and distinctive anatomical and mechanical cause 
for hemodynamic instability and circulatory volume loss in these two cohorts 
of patients (rAAAs and trauma). Anatomically, the majority of trauma victims 
(civilian and trauma) exhibit an ongoing and unopposed blood loss that can 
explain the significant hypotension and consequential hypo perfusion and 
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coagulopathy. However, 80% of patients with ruptured AAAs present with 
retroperitoneal rupture (posterior-lateral) and the aortic (infra renal) tear is 
often sealed and contained (Brewster, 2003; Rutherford, 1989). This permits a 
short phase of physiological and hemodynamic volume adjustment and 
accounts for the lack of profound circulatory shock in rAAAs. This tamponade 
effect could complement the presence of cut off blood pressure 
measurements noted in Montan et al. (2015) study. However, further research 
is required to ascertain the complex interplay of such variables (blood 
pressure, coagulation cascade and site of rupture) in this cohort of patients.   
 
Thirdly, aneurysm formation is a time depend pathophysiological process as 
opposed to sudden impact of trauma and its implications and its morphology 
alters and indulges the coagulation cascade constantly and chronically during 
its degeneration. The assault to the endothelium in aneurysm formation acts 
as a nidus for the adhesion and migration of platelets and generation of fibrin. 
The release of von Willebrand Factor (vWF) and the presence of various other 
hematological variables promote the activation of tissue factor (TF) 
(Edington,1991). Tissue factor that is expressed in the adventitia and the 
medial smooth muscle, generates thrombin formation through factors X and 
VII. In addition, the presence of mural thrombus during this process that 
exhibits a direct (positive) correlation to the aneurysm size and its anatomical 
tortuosity, activates the coagulation cascade furthermore (Mantovani, 1997; 
Yamazumi, 1998). Upon rupture, the loss of aortic wall integrity exposes the 
collagen and sub-endothelial matrix to more blood that results in significant 
and additional thrombin formation (Furie, 2008). This process can account for 
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the elevated serum levels of D-dimer or fibrin degradation product (FDP) in 
46.2% of the individuals in this review. 
 
The emerging literature that has evaluated the complex factors of coagulation 
in abdominal aortic aneurysms have highlighted that even the baseline 
coagulation of ruptured AAAs, are vastly different to those of non-ruptured 
cases. In two comparative studies, the markers of thrombin generation: 
Thrombin-anti-thrombin complex (TAT) and Pro-thrombin fragment (PF) 1+2 
concentration were statistically higher in rAAAs in comparison to the non-
ruptured cases (135.5 μg/L Vs. 61 μg/L, p≤ 0.02). This outcome was also 
noted in the markers of fibrinolysis (tissue- plasminogen activator antigen) 
(ruptured AAA 15.7 ng/mL vs. Non ruptured AAA 6.6 ng /mL, p≤ 0.05) 
(Skagius, 2007; Adam, 1999). Thus, suggests an activated coagulation 
cascade widely different to those noted in the trauma cohort.  
 
The initial resuscitation strategy most commonly adopted in rAAA patients 
across vascular units is “permissive hypotension” (Roberts, 2006). Such 
hypotension may well result in hypo-perfusion and early coagulopathy, 
although unlike trauma patients, evidence in the rAAA cohort demonstrates no 
significant relationship between hypotension and hypo perfusion with the 
degree of coagulopathy and fibrinolytic parameters. In addition, an earlier 
suggestion about elevation of fibrinolytic factors in rAAAs could be related to 
the application of supra-celiac cross clamp that in turn, reduces the hepatic 
blood flow and results in elevation of fibrinolytic factors (Gertler, 1996; Illig, 
1997). Furthermore, studies in the literature have suggested improved 
 66 
mortality, morbidity with minimal pre and perioperative blood loss as the result 
of systolic blood pressure titration between 70-100 mmHg as the part of the 
initial resuscitation strategy adopted in permissive hypotension of rAAAs 
(Riley, 2000; Dutton, 2002). 
 
Finally, another major variable that has been associated with significant 
coagulopathy is the presence of hypothermia. A high number of victims in the 
military and civilian trauma are exposed to a hostile and exposed environment 
with delayed presentation to the emergency services and hospital 
resuscitation facilities (Kheirbek, 2009; Wade, 2011).  Therefore, hypothermia 
might be more profound in this population as compared to rAAA patients that 
mainly present to emergency services direct from a controlled environment. 
 
Strengths & Limitations 
 
This is the first systematic review to investigate the baseline coagulation of 
ruptured abdominal aortic aneurysms in the literature. Despite the lack of 
statistical analysis (meta-analysis), this review can serve as a platform for 
future research. The careful application of recognized definitions provides 
future investigators with a more focused approach towards the topic in hand. 
This study is relatively low in power for an objective inference and a larger 
cohort would have been optimal. Furthermore, the level and grade of 
evidence according to NICE guidelines (Table 4.2) were suboptimal in two 
studies.  
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The included studies in this review did not report the serological markers of 
coagulation in a collective and a unified statistical manner. In addition, there 
appears to be a lack of consensus on the definition and interpretation of 
theoretical and clinical coagulopathy. Overall, the coagulation cascade is a 
complex interplay of various parameters and focus on a single factor in few 
included studies could not be a representative of the broader status alone. 
These factors should be assessed in context of other various markers of 
coagulation. This review emphasizes, the need for robust methodology in the 
future research.  
 
4.4 Conclusion 
In conclusion, the majority (≥ 85%) of ruptured abdominal aortic aneurysms 
do not present with coagulopathy. Amongst the individuals that do, significant 
coagulopathy is limited to only 6% with only 2.4% of the population 
demonstrating disseminated intravascular coagulation (DIC). Almost half of 
the population (46.2%) showed elevated levels of the D-dimer or fibrin 
degradation product (FDP) and the majority (97%) have normal concentration 
of fibrinogen. 
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CHAPTER 5 
 
The Clinical Implication of Blood Product Transfusion on 30-day 
Morbidity and Mortality of Ruptured Abdominal Aortic Aneurysm. 
 
 
 
5.1 Introduction 
Previous reports in the literature have suggested that mortality following the 
repair of ruptured abdominal aortic aneurysm (rAAA) has been predominantly 
due to hemorrhage secondary to coagulopathy. However, the current literature 
suggests that fatal hemorrhage secondary to coagulopathy is now rare and 
there has been a significant shift towards post procedure mortality and 
morbidity as a consequence of thrombotic complications (Davies, 1993; 
Henriksson, 2012). This has been attributed to the new transfusion and 
resuscitation techniques where crystalloids and colloids have been replaced by 
blood and blood component transfusion (Duchesne, 2008). 
The new transfusion (blood & blood component) protocols have evolved as a 
result of research surrounding military and civilian trauma patients with 
catastrophic hemorrhage, where a transfusion ratio of 2:1:1 and/or 1:1:1 of 
packed red blood cell (PRBC) to fresh frozen plasma (FFP) to platelets (PLT) 
conferred a mortality benefit (Duchesne, 2008). These protocols have since 
been used in the resuscitation of all patients presenting with hemorrhagic shock 
including those with rAAAs. Evidence suggests that the transfusion of packed 
red blood cells (PRBC) in rAAAs resuscitation has significantly reduced 
mortality however, (Fujita, 2012) the impact of the transfusion of FFP and PLT 
with the aforementioned ratio has yet to be determined. The aim of this study 
is to determine the effect of transfusion of blood and blood components such 
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as FFP and Platelets on the 30-day morbidity and mortality of patients 
presenting with rAAAs. 
 
5.2 Material & Methods 
A retrospective consecutive study of all patients presenting with ruptured infra-
renal AAA at Mid Essex Hospitals NHS Trust from November 2007 to June 
2015 was carried out. The hospital, surgical and anaesthetic database for all 
ruptured cases was searched and a total of ninety patients (n=90) were 
identified. However, only eighty-two (n=82) patients had a complete record. 
None of the patients were on any local screening programme and all patients 
had an open repair of the infra-renal ruptured abdominal aortic aneurysm. All 
individuals had a similar method of repair. A straight knitted Dacron graft 
according to the aorta size (size 16-20mm) was anastomosed proximally and 
distally with Polyprolene Monofilament suture size 3 and 4 respectively 
(SurgiproTM Covidien).  Furthermore, none of the patients had any known 
coagulopathy and/or haematological disorder. Eighty individuals (n=80) were 
on Aspirin 75 mgs preoperatively and none were on any other antiplatelet 
and/or anticoagulant medication. The transfusion policy was based on clinical 
expertise of the anaesthetic department and (not on any protocol) this was 
applicable to all individuals.  
The patient demographics on age, gender, co-morbidities, American society of 
Anesthesiology score (ASA), blood loss and blood component transfusions of 
units of Pack Red Blood Cell (PRBC), units of Fresh Frozen Plasma (FFP), and 
pools of Platelet (PLT) were retrieved. None of the individuals received any 
other additional clotting factors or were subjected to auto transfusion. All 
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patients received 5000 IU of heparin intravenously after the application of the 
aortic clamp. Postoperatively all patients received Aspirin 75mgs along with 
Enoxaparin Sodium 40mgs, subcutaneously once daily. Individual preoperative 
Computed tomography angiograms (CTA), of the entire cohort was assessed 
by two separate investigators (interventional vascular radiologist & consultant 
vascular surgeon) and the aneurysm size was calculated and presented in 
millimeters. The maximum diameter was taken as the true size of the AAA. The 
agreement level in size measurement was assessed using Cohen’s Kappa 
Coefficient (ĸ=0.82). The study endpoint was set at 30 days for all outcomes of 
mortality, morbidity (thrombotic and non-thrombotic complications). Morbidity 
was defined according Clavien-Dindo classification ≥3 (considered a major 
complication) (Dindo, 2004) Mortality was defined as death from any cause. 
Due to lack of any new or alternative intervention and availability of the data for 
clinical purpose ethical approval was granted with audit number CA13-226.  
   
Statistical Analysis 
For the purposes of the statistical analyses, scale variables were categorized 
according to their median values. Differences across the outcome groups were 
examined using Kruskal-Wallis and Chi Squared analyses. Logistic regression 
analyses were undertaken to determine factors associated with each outcome 
(30-day mortality, 30-day morbidity and 30-day thrombotic complications). Each 
variable was tested individually for association with the outcome. Those 
variables that demonstrated  
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    No Morbidity or 
Mortality 
30-Day 
Morbidity 
30-Day 
Mortality 
    n= % n= % n= % 
Gender Male 39 81.2% 17 77.3% 10 83.3% 
Female 9 18.8% 5 22.7% 2 16.7% 
Age 18-75 years 26 54.2% 12 54.5% 4 33.3% 
>75 years 22 45.8% 10 45.5% 8 66.7% 
ASA 2 13 27.1% 4 18.2% 0 0.0% 
3 20 41.7% 4 18.2% 3 25.0% 
4 12 25.0% 11 50.0% 7 58.3% 
5 3 6.2% 3 13.6% 2 16.7% 
PRBC (Unit) No Transfusion 9 19.1% 4 18.2% 2 16.7% 
1-3 Units 
Transfused 
23 48.9% 3 13.6% 1 8.3% 
>3 Units 
Transfused 
15 31.9% 15 68.2% 9 75.0% 
  
       
FFP (Unit) No Transfusion 23 48.9% 8 36.4% 1 8.3% 
1-3 Units 
Transfused 
12 25.5% 4 18.2% 3 25.0% 
>3 Units 
Transfused 
12 25.5% 10 45.5% 8 66.7% 
  
       
PLT (Pool) No Transfusion 32 66.7% 10 45.5% 3 25.0% 
1 or more pools 16 33.3% 12 54.5% 9 75.0% 
  
       
ITU Stay 
(hours) 
0-72 hours 25 71.4% 6 31.6% 3 27.3% 
>72 hours 10 28.6% 13 68.4% 8 72.7% 
  
       
Length of 
Stay (Days) 
0-10 days 31 66.0% 8 38.1% 4 33.3% 
>10 days 16 34.0% 13 61.9% 8 66.7% 
Table 5.1 Demographic detail of patients in each category. 
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a significance of p ≤0.10 were entered into a multivariable logistic regression 
model. At multivariable analyses, variables with a p value of p≤0.05 were 
deemed to be statistically significant and independently associated with the 
outcome. All statistical analyses were carried out using Statistical Package for 
the Social Sciences (SPSS), IBM version 22.0.  
 
5.3 Results: 
A total of 82 patients had complete data for analyses. The median age at time 
of rAAA was 75 years (range, 51-92). The majority of the population was male 
(n=66, 80.5%). The median size of rAAA was 75.52 mm (range, 40-100mm). 
The American Society of Anesthesiology score (ASA) in the order of prevalence 
was ASA=4 (n=36, 36.6%), ASA=3 (n=27, 32.9%), ASA=2 (n=17, 20.7%) and 
ASA=5 (n=8, 9.8%). Hypertension was found in 60.9%(n=50), chronic 
obstructive pulmonary disease (COPD) in 28.0% (n=23/82) and active smokers 
in 23.2% (n=19/82) of the cohort. The median intra-operative blood loss was 
2,100 ml (range, 500-5,000). The median length of intensive care unit stay was 
72 hours (range, 13-574) and the overall median length of hospital stay was 10 
days (range, 5-29) (Table 5.1). 
 
Mortality 
Overall 14.6% (n=12) died within the first 30-days of surgery. Of these, the vast 
majority (n=10/12) were males. Univariate analyses demonstrated increasing 
ASA score (p=0.028), transfusion of fresh frozen plasma of more 3 units 
(p=0.034) were significantly associate with mortality for the overall 14.6% 
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(n=12, male=10 vs. female= 2) mortality. At multivariable logistic regression 
only fresh frozen plasma (> 3 units) remained an independent predictor of 
mortality (OR, 11.27, CI (1.13-96.72), p=0.027) (Table 5.2). 
 
Morbidity  
A total of 22 patients (26.8% of the entire population) experienced morbidity 
within 30-days post rAAA surgery. Logistic regression analyses were 
undertaken to ascertain determinants of morbidity. Univariate analyses 
demonstrated transfusions of PRBC >3 units (p=0.008), FFP >3 units (p=0.006) 
and platelet >1 pool were significantly associated with 30-day morbidity (Table 
5.3). At multivariable level, no variable was found to be independently 
associated with 30-day morbidity. However, further sub-group analyses of 30-
day morbidity (thrombotic vs. non thrombotic complications) at multivariable 
regression analysis demonstrated transfusion of platelet pool of more than 1 is 
an independent predictor of thrombotic events (OR, 4.3, 95% CI: 1.37-13.6) 
p=0.012) accounting for 50% (n=11/22) of all morbidities and mortality (n=6/12) 
(Table 5.4). Postoperative thrombotic events (thromboembolic phenomenon) 
that lead to mortality were bowel ischemia (n=4) and limb ischemia (n=2). The 
others included, ischemic stroke (n=1), Ischemic myocardial infarction (n=1) 
and three (n=3) cases of renal artery thrombosis. The median length of stay for 
the deceased was 14 days (IQR8-23) as opposed to median of 8 days (IQR 6-
14) for patients that made it through the surgery. Their details are highlighted 
in table 5 of this manuscript. 
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    Univariate  Multivariate 
      OR CI p= 
Gender Male 0.788 1 (Ref) 
  
Female 
   
  
     
Age 18-75 years 0.188 1 (Ref) 
  
>75 years 
   
  
     
ASA Grade 2 0.028 1 (Ref) 
  
3 not 
estimable 
 
0.998 
4 not 
estimable 
 
0.998 
5 not 
estimable 
 
0.998 
  
     
COPD No COPD 0.660 1 (Ref) 
  
COPD 
   
  
     
Smoking 
Status 
Non-Smoker 0.871 1 (Ref) 
  
Smoker 
   
  
     
Blood Loss 
(mls) 
Up to 2L 0.534 1 (Ref) 
  
>2L 
   
  
     
Packed 
Red Blood 
Cells 
Transfused 
(Units) 
No Transfusion 0.168 1 (Ref) 
  
1-3 Units Transfused 
   
>3 Units Transfused 
   
  
     
Fresh 
Frozen 
Plasma 
Transfused 
(Units) 
No Transfusion 0.016 1 (Ref) 
  
1-3 Units Transfused 5.81 0.56-
60.48 
0.141 
>3 Units Transfused 11.27 1.31-
96.72 
0.027 
  
     
Platelets 
Transfused 
(Pools) 
No Transfusion 0.034 1 (Ref) 
  
1 or more pools 1.44 0.23-
9.04 
0.696 
Table 5.2 Regression analysis (Univariate & multivariate) on factors associated with 30-day 
mortality. 
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Logistic regression analysis: factors associated with 30-day morbidity 
    Univariate Multivariate 
      OR CI p= 
Gender Male 0.750 
   
Female 
  
  
     
Age 18-75 years 0.392 
   
>75 years 
  
  
     
Hypertension No Hypertension 0.272 
   
Hypertensive 
  
  
     
COPD No COPD 0.898 
   
COPD 
  
  
     
Smoking Status Non-Smoker 0.382 
   
Smoker 
  
  
     
Packed Red 
Blood Cells 
Transfused 
(Units) 
No Transfusion 0.008 1 (Ref) 
  
1-3 Units Transfused 0.27 0.06-
1.32 
0.106 
>3 Units Transfused 2.03 0.51-
8.0 
0.313 
  
     
Fresh Frozen 
Plasma 
Transfused 
(Units) 
No Transfusion 0.006 1 (Ref) 
  
1-3 Units Transfused 1.26 0.25-
6.35 
0.774 
>3 Units Transfused 0.79 0.12-
5.29 
0.806 
  
     
Platelets 
Transfused 
(Pools) 
No Transfusion 0.007 1 (Ref) 
  
1 or more pools 2.49 0.85-
7.31 
0.098 
Table 5.3. Regression analysis (Univariate & Multivariate) factors on 30-day Morbidity. 
 
 
 
 
 
 
 
 
 76 
5.4 Discussion: 
The outcome of this study suggests FFP transfusion coincides with increased 
risk of 30-day comorbidity, namely thrombo-embolic events. The traditional 
crystalloid/colloid infusion has now been replaced with PRBC, FFP and PLT 
which is based on massive transfusion protocols (Stansbury, 2009; Holcomb, 
2010). The initial strategy was aimed at the optimization of cardiac output and 
oxygen delivery system and later, at the correction of coagulopathy believed to 
develop several hours after the onset of hemorrhagic shock (Cosgriff, 1997; 
Ledgerwood, 2003). However, recent research suggests that traumatic 
coagulopathy in hemorrhagic shock is from the activation of anticoagulant 
protein C pathway due to tissue hypo-perfusion and not from the consumption 
of coagulation factors. Thus, the resuscitation protocols should now aim at 
limiting hypo perfusion and its duration, which can be assessed by the degree 
of acidosis (Brohi and Tieu, 2007). This means the new transfusion strategy 
aims at correcting the trauma triad of hypothermia, acidosis, and coagulopathy 
(Mikhail, 1999). 
 
The current transfusion strategy has reduced mortality from catastrophic 
hemorrhage in rAAA patients. However, with increased survival there has been 
an emergence of a new pattern of mortality and morbidity, which is related to 
thrombotic events. There is a degree of evidence to support the use of PRBCs 
in this cohort of patients. However, the difference between a traumatically 
injured and rAAA patient needs to be considered before the administration of 
other blood components like FFP and PLT (Henriksson, 2012).  In contrast to 
the trauma population, the average age in vascular patient is much higher (75 
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vs. 45 years), they exhibit far more comorbidities and they do not commonly 
present with hypothermia (Mell, 2010). Aneurysm formation is a time depend 
process and its morphology alters the coagulation cascade in comparison to 
the sudden impact of trauma on overall physiology and its immediate effect on 
the coagulation cascade.  
 
Furthermore, during aneurysm degeneration, the assault to the endothelium 
acts as a nidus for the adhesion of platelets, migration of platelets and 
generation of fibrin. The release of von Willebrandt Factor (vWF) and the 
presence of various other hematological factors promote the activation of tissue 
factor (TF) that in turn generates thrombin formation through factors X and VII. 
In addition, the size of mural thrombus exhibits a direct (positive) correlation to 
the aneurysm size and its anatomical tortuosity that are much higher in rAAA 
(Edington, 1991; Mantovani, 1997; Yamazumi, 1998). This indicates rAAAs 
present with a pro-coagulant rather than coagulopathic state and therefore do 
not require the current suggested ratio of FFP and PLT as a rule.  
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    Univariate Multivariate 
      OR CI p= 
Gender Male 0.319 
   
Female 
  
  
     
Age 18-75 years 0.345 
   
>75 years 
  
  
     
ASA Grade 2 0.182 
   
3 
  
4 
  
5 
  
  
     
Hypertension No Hypertension 0.249 
   
Hypertensive 
  
  
     
COPD No COPD 0.977 
   
COPD 
  
  
     
Smoking Status Non-Smoker 0.601 
   
Smoker 
  
  
     
Blood Loss (ml) Up to 2L 0.039 1 
(Ref) 
  
>2L 1.91 0.52-
7.07 
0.334 
  
     
Packed Red 
Blood Cells 
Transfused 
(Units) 
No Transfusion 0.559 
   
1-3 Units 
Transfused 
   
>3 Units 
Transfused 
   
  
     
Fresh Frozen 
Plasma 
Transfused 
(Units) 
No Transfusion 0.179 
   
1-3 Units 
Transfused 
   
>3 Units 
Transfused 
   
  
     
Platelets 
Transfused 
(Pools) 
No Transfusion 0.012 1 
(Ref) 
  
1 or more pools 4.33 1.37-
13.67 
0.012 
Table 5.4 Regression analysis (Univariate & Multivariate)  
on factors associated with thrombotic complications. 
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The initial resuscitation strategy most commonly adopted in rAAA patients 
across vascular units is “permissive hypotension” (Roberts, 2006). Such 
hypotension may well result in hypo-perfusion and early coagulopathy, 
although unlike trauma patients, evidence in the rAAA cohort demonstrates no 
significant relationship between hypotension and/or hypo perfusion, the degree 
of coagulopathy and fibrinolytic parameters. In addition, an earlier suggestion 
about elevation of fibrinolytic factors in rAAAs could be related to the application 
of supra-celiac cross clamp that in turn, reduces the hepatic blood flow and 
results in elevation of fibrinolytic factors (Gertler, 1996; Illig, 1997; Adam, 1999). 
 
In the study by Adam et al. (1999) even non-ruptured AAAs exhibited significant 
coagulation status difference to that of rAAAs. The markers of thrombin 
generation: Thrombin-anti-thrombin complex (TAT) and Pro-thrombin fragment 
(PF) 1+2 concentration were statistically higher in rAAAs in comparison to the 
non-ruptured cases (135.5 μg/L Vs. 61 μg/L, p≤ 0.02). This was also significant 
in the markers of fibrinolysis (tissue- plasminogen activator antigen) (15.7 
ng/mL vs. 6.6 ng /mL, p≤ 0.05) (Adam, 1999). The above data in addition to the 
earlier discussion, demonstrates that unlike the trauma group of patients, AAA 
individuals are pro-coagulant and more so if they are in ruptured circumstances. 
It appears that such a pro-coagulant state persists throughout the operation 
and resolves in the postoperative period (≥ 24 hours) (Adam, 1999). Therefore, 
liberal or extensive use of fresh frozen plasma (FFP) and platelets may well 
contribute to postoperative thrombotic events and mortality.  
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Data suggests that FFP transfusion of more than three units is an independent 
predictor of 30-day mortality in rAAAs. Other authors have reported similar 
results. In a study comparing the number and types of transfusions of survivor 
and non-survivor groups in rAAA, the authors demonstrated the unit of FFP 
transfused in the survivor group to be significantly lower than the non-survivor 
group. The postoperative complications leading to mortality in the study by 
Fransson et al. (2012), was related to micro and macro cardiovascular 
thrombotic complications. In the same direction, Kauvar et al. (2012) study 
could not establish a reduction in mortality with increase FFP transfusion in 
rAAA patients (p≥ 0.56). Furthermore, the study by Holcomb et al. (2008) 
highlighted that the new transfusion protocols could not address other 
contributing independent impacts of FFP on the endothelial structure, 
fibrinolysis, plasma proteins and increase platelet count on their effect on the 
overall mortality. The use of FFP transfusion as a volume replacement in 
addition to PRBC also seems to have no rationale in the literature.  
 
Another important issue surrounding the repair of rAAA is the use of un-
fractionated heparin. It appears that other than tissue plasminogen activator (t-
PA) no other fibrinolytic component is affected by heparin. Considering the 
status of rAAA and the potential loss of significant volume, surgeons are 
reluctant to use heparin in such settings. The judicial use of heparin after the 
application of the aortic clamp may reverse and/or decrease the pro-coagulant 
state and the associated mortality induced by higher FFP transfusion. In our 
cohort all individuals received Heparin and this may justify the lower mortality 
incidences compared to the other reported series. Graham et al. review also 
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recommends the use of heparin in the repair of rAAA for the reversal of the 
ongoing pro coagulant state and post procedural thrombotic events (Marsh, 
1990; Thompson, 1996).  
 
Platelet transfusion of more than one pool was an independent marker of 
thrombotic complications in our cohort of patients. In a recent analysis of 
preoperative bloods (Platelet count, Prothrombin time (PT), activated partial 
thromboplastin time (APTT) performed on individuals with rAAAs, no 
coagulopathic state was identified. In addition, no thrombocytopenia and/or 
platelet count of less than 100 10/l was noted in the majority of the individuals 
(Reed, 2013). This outcome clearly indicates that patient with rAAA, do not 
necessarily require active platelet transfusion and if so it has to be based on 
ongoing laboratory result rather than one for all transfusion protocol. In addition, 
active transfusion of platelet in a patient with adequate platelet count for a major 
surgery could explain the ongoing trend and shift towards the occurring 
thrombotic complications in our cohort.  
 
The current study has several strengths and weaknesses. This is the first study 
in the literature that has evaluated the role of PRBC, FFP and PLT (massive 
transfusion protocol and its ratio) in the resuscitation of rAAAs. Data appears 
to be in agreement with earlier studies indicating that rAAAs unlike trauma 
patients are pro-coagulant and liberal use of FFP and PLT can contribute to 
mortality, morbidity and thrombotic complications. In addition, this study 
highlights that the mortality incidence of rAAA has improved and these patients 
are no longer succumbing to hemorrhagic shock, but instead are expiring as a 
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result of thrombotic complications later in the recovery phase. This study 
inherits the weakness of being retrospective in nature and a higher number of 
individuals in a randomized controlled trial would have been optimal. However, 
given the nature of the surgery, its associated high morbidity and mortality, such 
methodology might not feasible. 
  
n= %   
    
Gender Male 10 83.3%  
Female 2 16.7%   
    
Age 18-75 years 4 33.3%  
>75 years 8 66.7%   
    
ASA Grade 2 0 0.0%  
3 3 25.0%  
4 7 58.3%  
5 2 16.7%   
    
Hypertension No Hypertension 8 66.7%  
Hypertensive 4 33.3%   
    
COPD No COPD 8 66.7%  
COPD 4 33.3%   
    
Smoking 
Status 
Non-Smoker 9 75.0% 
 
Smoker 3 25.0%   
    
Blood Loss Up to 2L 5 41.7%  
>2L 7 58.3%   
    
PRBC No Transfusion 2 16.7%  
1-3 Units Transfused 1 8.3%  
>3 Units Transfused 9 75.0%   
    
FFP No Transfusion 1 8.3%  
1-3 Units Transfused 3 25.0%  
>3 Units Transfused 8 66.7%   
    
PLT No Transfusion 3 25.0%  
1 or More Pools 9 75.0%   
    
HB  Up to 115 g/l 8 66.7%  
>115 g/l 4 33.3% 
Table 5.5 Information on the deceased patients (n=12). 
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Age Sex HB HT  Platelet PTT APTT INR 
87 Female 8.8 0.300 168 13.1 37.3 1.10 
88 Male 9.4 0.271 65 14.9 50.9 1.25 
82 Male 9.6 0.244 140 13.3 28.2 1.12 
76 Male 10.5 0.313 99 16.7 47.9 1.40 
74 Male 12.0 0.376 149 12.8 25.0 1.07 
72 Male 14.7 0.264 136 11.3 27.5 1.01 
87 Male 7.0 0.210 35 32.6 240.0 1.20 
75 Female 11.6 0.380 69 16.6 36.0 1.45 
80 Male 10.7 0.340 177 24.9 113.3 2.34 
85 Male 10.4 0.230 190 16.3 46.6 1.42 
64 Male 14.8 0.430 146 14.5 24.1 1.23 
Table 5.6. Laboratory results of deceased  
Patients prior to transfusion. 
 
5.5 Conclusion 
The findings of this study are that certain blood products such as FFP and 
platelets may be associated with increased postoperative morbidity post rAAA 
repair. The traditional transfusion protocol and its suggested ratios of blood 
products to PRBC need to be questioned. Despite reduction in mortality 
associated with transfusion of PRBC, the use of other blood components such 
as FFP and PLT should be considered in the context of the patient’s 
requirement based on clinical and laboratory data. The liberal use of FFP and 
PLT in rAAA patients might have a different outcome to that of trauma patients. 
Thus, further research assessing such factors is required to determine what the 
ideal transfusion protocol would be. 
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CHAPTER 6 
 
Blood markers on 30-day mortality & morbidity of ruptured 
abdominal aortic aneurysm: A retro & prospective cohort 
study. 
   
6.1 Introduction 
To deliver a more personalized form of vascular care, there is a need to identify 
novel, readily available and consistent predictive factors for risk stratification in 
rAAA surgery. In recent years there has been an accumulating level of evidence 
that elevated levels of systemic inflammatory response (SIR) are associated 
with increased cardiovascular incidents (Duffy, 2006).  The Neutrophil to 
Lymphocyte ratio (NLR) first reported in 1967, is a widely used marker of SIR 
in recent literature (Bobb, 1967). The NLR has been linked to adverse 
outcomes in patients with colorectal, gastric, pancreatic, ovarian and 
hepatocellular carcinoma (Gomez, 2008; An, 2010; Malietzis, 2013).  
 
In relation to vascular surgery, there is a single study that demonstrates NLR is 
a predictor of 2-year survival in patients undergoing a range of vascular 
interventions (Bhutta, 2011). In addition, a recent report suggests that in the 
elective group of AAAs, a preoperative NLR> 5 could be a predictor of 30-day 
mortality (Appleton, 2014). Although there is emerging evidence to support the 
prognostic importance of NLR in the outcomes of a patient having a vascular 
procedure, no study has examined the role of NLR on patients with ruptured 
infra-renal abdominal aortic aneurysms (rAAA).  
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The aim of this study is therefore to assess the predictive value of NLR in 
relation to 30-day morbidity and mortality of patients undergone repair of 
ruptured infra-renal abdominal aortic aneurysms (rAAA). 
 
6.2 Material & Methods: 
A retrospective consecutive cohort study of all ruptured infra-renal AAA from 
November 2007 to June 2015 that presented for repair at Mid Essex Hospital 
NHS Trust with estimated population coverage of 360,000 was designed. The 
hospital, surgical and anesthetic dataset for all ruptured cases was searched 
and a total of eighty patients (n=80) were identified. None of the patients were 
on any local screening programme and all patients had an open repair of the 
ruptured aneurysm. None of the patients exhibited any loss of consciousness 
prior to the operation.  The data on age, sex, AAA size, blood loss, length of 
stay (LOS) and comorbidities (hypertension (HTN), active smoking (S), renal 
failure (RF), chronic obstructive pulmonary disease (COPD)) were recruited. A 
full blood count (FBC) was obtained preoperatively on all individuals and the 
NLR was calculated by dividing the Neutrophil by Lymphocyte count to obtain 
a ratio. Individual preoperative computed tomography angiogram (CTA) of the 
entire cohort was assessed by two separate investigators (interventional 
vascular radiologist & consultant vascular surgeon) and the aneurysm size was 
calculated and presented in millimeters. The maximum diameter was taken as 
the true size of the AAA. The agreement level in size measurement was 
assessed using Cohen’s Kappa Coefficient (ĸ=0.78).  The primary study 
endpoint was set at 30-day morbidity and mortality, measured from the time of 
surgery.  Morbidity was defined according Clavien-Dindo (2004) classification 
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≥3 (considered a major complication). Due to lack of any new or alternative 
intervention and availability of the data for clinical purpose ethical approval was 
granted with audit number CA13-226.  
 
Statistical Analysis  
The primary study end point was 30d morbidity and mortality. I determined the 
optimal discriminator value for NLR using receiver operating characteristic 
(ROC) curve analysis. At each value, the sensitivity and specificity for each 
outcome under study were plotted. The ratio closest to the point with maximum 
sensitivity and specificity was selected as the cutoff value. The relationship 
between NLR and other clinical parameters was assessed using nonparametric 
statistics. Stepwise multivariate logistic regression analysis was performed. 
The level of significance permitting multivariate analysis inclusion and the 
statistical significance for all other tests used was set at P < 0.1. All analyses 
were performed using the statistical software, Statistical Package for the Social 
Sciences, version 20.0 (SPSS, Inc, Chicago, IL).  
 
6.3 Results 
The median patient age was 75 (range, 51 to 92) with 82.5% of the population 
being male (n=66/80). Of the total cohort forty-three patients (64.2%) were 
hypertensive (HTN). Out of the nineteen active smokers (25%), seventeen 
patients (n=17, 21.8%) had the confirmed diagnosis of COPD.  
Preoperative acute renal failure was noted in three patients (3.9%). The 
median AAA size in millimeters was 75.50 mms (range, 45 to 120 mm). The 
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median preoperative hemoglobin was 11.3 mg/dl (range, 4.5 to 16 mg/dl). 
Total intraoperative blood loss was 2500ml (range 500ml to 5620ml).  
Table 1. The median intensive care unit (ITU) stay was 72 hours and the 
median duration in hospital stay was 13 days. The overall 30-day morbidity 
was 51.2% (n=41/80) and the overall 30-day mortality was 13.8% (n=11/80) 
(Table 6.1). 
 
An ROC curve analysis was performed in relation to the presence of 30d 
mortality and morbidity. For all 80 rAAAs, an NLR of 5.0 had the highest 
sensitivity and specificity for both outcomes. Thereafter, patients were stratified 
into 2 groups: low NLR (≤5) and high NLR (>5). Table 6.2 shows the difference 
in clinic-pathological features of the two NLR groups. Overall, 25 patients 
(31.2%) had a low NLR and 55 patients (68.8%) had a high NLR. A high NLR 
was significantly associated with low Hemoglobin (Hb) levels and it was not 
associated with sex, age, AAA size, history of HTN, COPD, smoking and Renal 
failure. Patients with HNLR had higher 30d morbidity compare with the LNLR 
group (35 Vs. 6, p=0.001) but no difference in the other short term outcomes 
studies such as intraoperative blood loss, Intensive care unit stay, primary 
length of stay and 30-day mortality. 
  
To investigate whether the NLR was associated with clinical outcome, 
univariate and multivariate logistic regression analysis for 30-day morbidity 
were performed. Analysis for 30d mortality was not performed due to the small 
number of events i.e. 30-day deaths. Univariate analysis identified the presence 
of HTN history (OR=0.39, 95%CI (0.14-1.14), p=0.08) as a negative and high 
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NLR (OR=5.54, 95%(1.9-10.15), p=0.02) as poor prognostic indicators of 30d 
morbidity.  
 To determine the independent prognostic significance of NLR on 30-day 
morbidity, multivariate analysis using a binary logistic regression model was 
performed. Multivariate analysis included HTN history and NLR. Only NLR 
variable was an independent prognostic factors for 30d morbidity (OR=4.28, 
95% (1.27-14.42), p=0.02) as outlined in Table 6.3. 
 
6.4 Discussion: 
To the best of my knowledge, this is the first study that has evaluated the 
predictive role of NLR in rAAA.  The outcome suggests that NLR > 5 is an 
independent predictor of post-operative morbidity. This appears to compliment 
the work of Appleton et al. (2014) where a NLR > 5 was associated with 
significantly higher mortality and a lower 2-year survival as a consequence of 
morbidity in the elective repair of infra-renal abdominal aortic aneurysms (AAA). 
Ruptured abdominal aortic aneurysms are a major cause of mortality in the 
western hemisphere and currently account for 2% of all deaths in the UK (Office 
of population Census and Surveys. Mortality Statistics: cause, England and 
Wales). Despite advances in the field of vascular surgery and allied health the 
cumulative perioperative mortality still persists at 40-50% and in some series 
up-to 80% (Norman, 2004; Sakalihasan, 2005). Assessment of such patients is 
rapid and remains subjective.  Risk stratification of rAAAs has led to the 
development of various score designs. Three such models are the Edinburgh 
Ruptured Aneurysm Score (ERAS), Hardman Index (HI) and Glasgow 
Aneurysm Score (GAS) (Samy, 1994; Hardman, 1996; Tambyraja, 2008). 
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However, the study by Gatt et al. (2009) demonstrated that HI and GAS are poor 
predictors of outcome after rAAA repair and no thorough validation of  
ERAS in another cohort has been performed. None of these scoring systems 
assess the inflammatory response in their analysis. 
 
 
Table 6.1 Patients Demographics. 
 Median 25
% 
75% Count Percentage 
Sex Female    14 17.5% 
Male    66 82.5% 
HTN No    24 35.8% 
Yes    43 64.2% 
C
O
P
D 
No    61 78.2% 
Yes    17 21.8% 
Smoking No    57 75.0% 
Yes    19 25.0% 
Renal 
Failure 
No    73 96.1% 
Yes 
 
   3 3.9% 
AAA size in mm 75.50 65.
00 
87.50   
Hb 11.30 9.5
0 
13.30   
NLR 9.40 4.1
4 
13.69   
Blood Loss (ml) 2500 150
0 
4750   
ITU stay (hours) 72 24 176   
LOS (days) 13 8 23   
30-day 
Morbidity 
None    39 48.8% 
Yes    41 51.2% 
30-day 
Mortality 
No    69 86.2% 
Yes    11 13.8% 
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LN
LR
 
H
N
LR
 
p-value 
M
edi
an 
Percentil
e 25 
Percentil
e 75 
N
= 
%
 
M
edian 
Percentil
e 25 
Percentil
e 75 
N
= 
%
 
 
A
ge 
76.00 
72.00 
87.00 
 
 
75.00 
69.00 
81.00 
 
 
0.301 
Sex 
Fem
ale 
 
 
 
5 
20.0%
 
 
 
 
9 
16.4%
 
0.755 
M
ale 
 
 
 
20 
80.0%
 
 
 
 
46 
83.6%
 
 
H
TN
 
N
o 
 
 
 
4 
23.5%
 
 
 
 
20 
40.0%
 
 
Yes 
 
 
 
13 
76.5%
 
 
 
 
30 
60.0%
 
0.221 
C
O
PD
 
N
o 
 
 
 
19 
76.0%
 
 
 
 
42 
79.2%
 
 
Yes 
 
 
 
6 
24.0%
 
 
 
 
11 
20.8%
 
0.746 
Sm
oking 
N
o 
 
 
 
17 
70.8%
 
 
 
 
40 
76.9%
 
 
Yes 
 
 
 
7 
29.2%
 
 
 
 
12 
23.1%
 
0.569 
R
enal 
Failure 
N
o 
 
 
 
23 
95.8%
 
 
 
 
50 
96.2%
 
 
Yes 
 
 
 
1 
4.2%
 
 
 
 
2 
3.8%
 
0.686 
A
A
A
 size (m
illim
eters) 
80.00 
60.00 
88.00 
 
 
75.00 
65.00 
85.00 
 
 
0.942 
H
b 
13.25 
11.35 
14.05 
 
 
11.00 
9.10 
12.20 
 
 
0.001 
B
lood Loss (m
L) 
2500 
1500 
3500 
 
 
3000 
1500 
5000 
 
 
0.606 
ITU
 stay (H
ours) 
57 
24 
96 
 
 
94 
32 
192 
 
 
0.205 
LO
S (D
ays) 
11 
9 
20 
 
 
13 
8 
23 
 
 
0.867 
30-day 
M
orbidity 
N
one 
 
 
 
19 
76.0%
 
 
 
 
20 
36.4%
 
 
Yes 
 
 
 
6 
24.0%
 
 
 
 
35 
63.6%
 
0.001 
30-day 
M
ortality 
N
o 
 
 
 
23 
92.0%
 
 
 
 
46 
83.6%
 
 
Yes 
 
 
 
2 
8.0%
 
 
 
 
9 
16.4%
 
0.488 
Table 6.2 C
linical features &
 outcom
es of patients w
ith high &
 low
 N
LR
s included. 
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In recent years the role of NLR as an independent predictor of mortality 
and morbidity has gained significant attention in colorectal, upper GI and 
cancer surgery. The use of this single and inexpensive prognostic factor 
has been on the rise in clinical and academic settings. In relation to 
cardiovascular surgery, recent evidence suggests that a raised NLR 
(NLR > 5) is associated with poorer survival following coronary artery 
bypass grafting (CABG) (Janion, 2007). In vascular surgery, Bhutta et 
al. (2011) assessment of 1021 individuals undergoing vascular 
interventions (non-emergency) revealed a lower independent 2-year 
survival in patients with NLR > 5. This has been attributed to the direct 
relationship between leucocytes and adverse cardiovascular outcomes 
such as myocardial infarction, coronary artery ectasia, arrhythmia, p-
wave depressions and its sequelae (Janion, 2007; Papa, 2008; Isik, 
2013). This appears to be in line with complications noted in our data 
irrespective of the age, gender, AAA size, comorbidities (COPD, HTN, 
RF, AS), blood loss, length of hospital and ITU stay of the entire cohort. 
 
Aneurysmal degeneration of the abdominal aorta is a time dependent 
process and NLR represents a chronic and a low-grade systemic 
inflammatory response. Neutrophilia has been associated with collagen 
remodeling, direct endothelial cell injury, pro-thrombotic state and 
hypercoagulability which is known to occur in rAAAs (Siminiak, 1995; 
Madjid, 2004; Coller, 2005). Neutrophilia is the product of neutrophil de-
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margination, delayed apoptosis and stimulation of stem cells by 
interleukin 6 (IL-6) and granulocyte colony stimulating 
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factors (G-CSF). Sudden neutrophilia could be a representative of acute on 
chronic inflammatory response as neutrophils encourage plaque rupture by 
releasing arachidonic acid derivatives and proteolytic enzymes. In addition, 
Haumer et al. study demonstrated increased neutrophil activation as a 
consequence of endothelial cell injury in formation of micro and macro vascular 
occlusive plugs (Haumer, 2005). 
 
Chung et al. (2010) review of 252 thoracic endovascular aneurysm repairs 
(TEVAR) demonstrated preoperative leukocytosis to be an independent marker 
of overall mortality. Recent literature suggests low lymphocyte to be associated 
with poor outcome in patients with cardiac pathology (Ischemic heart disease) 
(Evans,1995). Lymphocytopenia appears to be the result of redistribution and 
margination of lymphocytes within the lymphatic system and a marker of 
accelerated apoptosis. Low lymphocyte count indicates a state of 
immunosuppression and physiological stress that have adverse relation to 
overall patient outcome. Analysis of the components contributing to a raised 
NLR in this series suggests that neutrophilia is much more significant than 
lymphocytopenia (compared to their base line) and low Hb might be a surrogate 
marker of the severity of the rupture despite its statistical insignificance (Onmen, 
1997). 
 
The examination of a single, readily available, inexpensive index of NLR during 
the rapid assessment of rAAAs might be more feasible than calculation of a 
multifactorial scoring system in clinical practice. Despite accumulating evidence 
in support of high NLR; as a marker of worse outcome in elective and rAAAs, 
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whether preoperative NLR can be altered before intervention and consequently 
influence outcome remains to be establish. Further research, assessing this on 
a cellular and systemic level might be advocated. The authors believe there are 
some limitations to the current research. The low number of individuals (n=80) 
the retrospective methodology and the small percentage of missing data might 
subject this study to statistical bias. Therefore, future research should aim at 
recruiting a higher number of subjects and perhaps in a randomized controlled 
trial setting. However, given the nature of rAAAs and its associated high mortality 
and morbidity such methodology might not be feasible.  
 
In summary, no single prognostic marker or scoring system could be a complete 
replacement for the surgeon to patient clinical assessment and decision-making 
process. However, in an era where service provision, utilization of resources and 
informed consent is based on statistical outcomes, NLR might prove to be of 
clinical importance.  
 
6.5 Conclusion: 
 
A preoperative NLR> 5, irrespective of the age, gender, AAA size, blood loos, 
length of stay and comorbidities is an independent marker of 30-day morbidity 
and not mortality in ruptured abdominal aortic aneurysms. 
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CHAPTER 7 
 
Pre & Post Coagulation Profile Following Blood Component Transfusion 
in Ruptured Abdominal Aortic Aneurysm Irrespective of the Outcomes of 
30-Day Mortality & Morbidity.  
 
 
 
7.1 Introduction  
Prior studies evaluating the clinical impact of blood product transfusion 
indicated that both blood product components (fresh frozen plasma and 
platelet) as part of hemostatic resuscitation could independently contribute to 
mortality and morbidity (Kordzadeh, 2016). The overall aim of such protocols is 
to correct the suspected coagulopathy of rAAAs. Irrespective of earlier findings 
with regards to minimal coagulopathy, mortality and morbidity associated with 
such protocols, the aim of this current study is to assess whether such 
products actually do have any impact on the correction of identified 
coagulopathic individuals.  
 
7.2 Material and Methods 
A retrospective study of n=101 consecutive patients with suspected infra renal 
ruptured abdominal aortic aneurysm (rAAA) from November 2007 to June 2015 
that presented to the emergency department was conducted. Five patients 
(n=5) were deemed to be for palliation and another five (n=5) did not have any 
preoperative blood assessment. Eight patients (n=8) had mixed picture of 
abdominal and/or iliac and/or supra renal and/or tender aneurysm and were 
excluded from the study. The remaining individuals (n=82) had confirmed 
clinical and radiological infra-renal AAA rupture. The Mid Essex Hospital 
services NHS Trust, has estimated population coverage of 380,000 people.  
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Data on patient demographics (age and gender), comorbidities (Hypertension 
(HTN), Chronic obstructive pulmonary disease (COPD), Active smoking, 
coagulation profile (Prothrombin time (PT), Activated partial thromboplastin 
time (APTT), International normalized ratio (INR), Haemoglobin (Hb), platelet 
count (Plt) were recorded. Following the identification of patients with 
coagulopathy the immediate postoperative data on coagulation profile 
(Prothrombin time (PT), Activated partial thromboplastin time (APTT), 
International normalized ratio (INR), Haemoglobin (Hb), platelet count (Plt), 
blood and blood component transfusion were also recorded.  
 
Statistical Analysis 
Statistical analyses were undertaken using IBM Statistical Package for the 
Social Sciences (SPSS) version 21.0. Scale variables such as age, haemoglobin 
(Hb), platelet count (Plt), haematocrit (Ht), prothrombin time (PT), Activated 
partial thromboplastin time (aPTT) and international normalisation (INR) were 
categorised according to their respective median values and presented with inter 
quartile range (IQR). Upon recognition of the coagulopathy group, a paired t test 
was performed to evaluate the impact of blood and blood component transfusion 
on respective values of platelet count (Plt), haematocrit (Ht), prothrombin time 
(PT), Activated partial thromboplastin time (aPTT) and international 
normalisation (INR) (before and after). A p value of 0.05 or less was deemed to 
be statistically significant at 95% confidence interval. 
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7.3 Results 
The median age of the cohort was 75 years (IQR, 51-92) with male 
predominance (male n=66, 85% vs. female n=16, 19.5%, Table 1). The median 
size of rAAA was 75.52 mm (IQR, 40-100). Pre-existing hypertension was found 
in 60.9%, n=50, chronic obstructive pulmonary disease (COPD) in 28 %, n=23, 
active smokers in 23%, n=19 and acute renal failure was noted in three patients 
(3.9%). The median presenting value for Hb prior to operation was 11.3 mg/dl 
(IQR, 9.45-13.3,) whilst the median platelet count was 176×109/l (IQR, 122×109/l 
-210×109/l). The median value for PT was 13.1 (IQR, 10.1-35, mean= 14.79), for 
APTT was 29.55 (IQR 20.4- 240, mean=34.7) and for INR was 1.12 (IQR, 0.9-
2.91, mean= 1.25).  
   
    n= % 
Gender Male 12 85.7% 
Female 2 14.3% 
    
  
Age 18-75 years 5 35.7% 
>75 years 9 64.3% 
    
  
ASA Grade 2 2 14.3% 
3 2 14.3% 
4 6 42.9% 
5 4 28.6% 
    
  
Hypertension No Hypertension 7 50.0% 
Hypertensive 7 50.0% 
    
  
COPD No COPD 13 92.9% 
COPD 1 7.1% 
    
  
Smoking 
Status 
Non-Smoker 12 85.7% 
Smoker 2 14.3% 
    
  
Hemoglobin 
Pre-Op 
Up to 11.5g/l 9 64.3% 
>11.5g/l 5 35.7% 
Table 7.1 Demographic of patients  
with coagulopathy(n=14/82) 
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Pre Transfusion Coagulation Profile  
According to the defined parameters only 17.1% (n=14/82) of the entire cohort 
was found to have coagulopathy (INR>1.2 and PLT< 150×109/l). Only one 
patient was found to have significant coagulopathy (INR>1.5 and PLT 
<100×109/l) (Table 7.1) (Table 7.2). The median value for Hemoglobin (Hb) 
was 9.95mg/dl (IQR, 6.9 to14.8), for PT was 15.3 (IQR, 14.5 to 35), for aPTT 
34.55 (IQR, 24.1 to 69.4), Plt 113.5×109/l (IQR,62-146×109/l) and for INR was 
1.35 (IQR, 1.22 to 2.91). 
 
Age Sex AAAsize Platelet HB PT APTT INR 
88 M 90 65 9.4 14.9 50.9 1.25 
88 M 70 116 6.9 35 30 2.91 
87 M 60 116 6.9 35 30 2.91 
87 M 53 145 13.3 15.4 26.9 1.31 
80 M 90 113 13.7 16 33.1 1.34 
78 F 60 114 4.5 18.5 50.9 1.64 
76 M 84 95 11.3 15.3 30.1 1.28 
76 M 80 99 10.5 16.7 47.9 1.4 
76 M 70 135 9.1 19.6 51.9 
 
75 F 100 69 11.6 16.6 36 1.45 
71 M 90 62 7.6 24.3 69.4 2.03 
68 M 95 72 12.5 14.6 31.5 1.22 
64 M 80 146 14.8 14.5 24.1 1.23 
63 M 65 122 7.8 15.7 39 1.35 
*AAA size is in mms. 
Table 7.2 Age, gender & coagulation profile of patients  
(Prior to transfusion of blood & blood component transfusion). 
 
 
Post Transfusion Coagulation Profile  
 
Following the transfusion of blood and blood component products (Table 7.4) 
in 14 individuals that were found to be coagluopathic according to the defined 
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parameters, nine individuals (n=9/14, 64%) were still found to be in 
coagulopathy following the repair of rAAAs. The median value for Hb was 10.3 
mg/dl (IQR, 7.5 to 12.9), for PT was 16.1 (IQR, 13.1 to 22.9), for aPTT 32.6 
(IQR, 25.7 to 123), Plt 95×109/l (IQR,46-275×109/l) and for INR was 1.31 (IQR, 
1.1 to 2.5). 
 
 
Age Sex Platelet Hb PT APTT INR 
88 M 89 12.9 13.1 34.3 1.1 
88 M 126 9.5 16.5 25.7 1.38 
87 M 116 10.5 17.5 27.7 1.46 
87 M 
 
 
   
80 M 74 12.4 14.9 29.7 1.25 
78 F 82 7.5 16.9 44.7 1.49 
76 M 95 11.3 15.3 30.1 1.28 
76 M 115 10.1 16.1 32.6 1.35 
76 M 160 11 21.8 46.5 ? 
75 F 275 10.3 22.9 26.4 2.15 
71 M 58 9.6 13.8 33.4 1.16 
68 M 84 11.4 13.2 29.4 1.11 
64 M 109 8.4 14.3 39.1 1.21 
63 M 46 7.8 19 123.5 1.7 
Table 7.3 Age, gender & coagulation profile of patients 
(Post transfusion of blood & blood component transfusion). 
 
 
 
 
 
Age Sex PRBC FFP PLT 
88 M 11 14 2 
88 M 5 4 1 
87 M 5 4 1 
87 M 2 0 0 
80 M 14 4 2 
78 F 
   
76 M 10 6 0 
76 M 0 7 1 
76 M 16 4 3 
75 F 10 4 0 
71 M 14 6 2 
68 M 12 4 2 
64 M 12 2 2 
63 M       
* The empty space indicates the lack of data  
Table 7.4 Details of blood & blood component  
transfusion in all coagulopathic patients. 
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Impact of Transfusion 
  
Statistical analysis demonstrated no significant change of coagulation profile 
(coagulopathy) following transfusion of blood and blood component transfusion 
in any values of PT (p=0.53), aPPT (p=0.98), INR (p=0.17) and Plt (p=0.66) at 
95% confidence interval (Table 7.5).  
 
 
 
  
P value Markers 
/Mean 
Std. D Std. 
Error 
Mean 
95% Confidence Interval 
Lower Upper  
Pre & post 
PT/1.6 
9.4949
3 
2.53763 -3.85007 7.11435 .531 
Pre & post 
aPPT/ 
0.13077 
27.943
68 
7.75018 -16.75542 17.01696 .987 
Pre & Post 
INR/ 0.28083 
.66977 .19335 -.14472 .70638 .174 
Pre & Post 
Plt/ -8.07692 
66.454
82 
18.43125 -48.23517 32.08132 .669 
Table 7.5 Paired t-test analysis of pre & post transfusion 
of blood & blood component transfusion. 
 
7.4 Discussion 
 
The findings of this study demonstrates that transfusion of blood products of 
fresh frozen plasma and platelet has no impact on correction of coagulopathy 
in limited number of individuals (n=14) that do present with such status. Fresh 
frozen plasma (FFP) normally contains two important components, namely 
factor V and factor VIII (Mumford et al., 2014). The use of FFP remains vital in 
known coagulation disorders of factor V, Antithrombin III deficiency and 
reversal of anticoagulants such as warfarin (Keeling et al., 2011). Despite 
these findings, their empiric use as a part of massive transfusion protocol has 
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been on the rise in last one decade (Duchesne et al.,2008). The depletion of 
coagulation factors of V and VIII in patients with hemorrhagic shock are not 
common and the majority of coagulation disorders are secondary to the loss of 
circulatory volume and its subsequent effect on platelet count. The universal 
transfusion of FFP to reverse hemostatic disorders should be limited to 
individuals with known factor deficiencies (factor V and VIII) and/or 
replacement of presumed depleted factors (Keeling et al., 2011). The finding of 
this study appears to complement earlier research that prophylactic transfusion 
of FFP as a part of set transfusion ratio in not indicated and may result in 
adverse outcomes in rAAAs (Kordzadeh, 2015: Calballero, 2014). 
Furthermore, the transfusion of FFP irrespective of the cause of the 
hemorrhage could contribute to transfusion related acute lung injury (TRALI), 
increase surgical wound infections and cardiac failure (Rudman, 2005). In 
exceedingly dire circumstances where no information on patient past medical 
history is available (factor V deficiency, Warfarin use), the use of FFP in 
combination to packed red blood cells and/ or instead may be justifiable. 
However, in cases of ruptured abdominal aortic aneurysm and availability of 
various hematological tests during the perioperative period this might not be 
clinically recommended. Another argument might be, once a patient had 
massive transfusion of PRBCs, some derangements of factors might 
eventually occur and transfusions of FFP might be advisable. However, in 
cases of ruptured abdominal aortic aneurysm, the major factor is limitation of 
further circulatory volume depletion and if not perioperative blood test could aid 
in prompt identification of hematological deficiencies (Assar and Zarins, 2009). 
Overall, it appears that the use of FFP in resuscitation of rAAAs is not evidence 
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based and their empirical use should be limited to known coagulation 
disorders.  
 
According to the definition of coagulopathy (Greuters, 2011; Hunt, 2014)., only 
one patient was identified to suffer from severe coagulopathy (INR>1.5 and 
PLT <100×109/l) on arrival to the emergency department whereas the rest of 
the cohort had mild coagulopathy (INR>1.2 and PLT< 150×109/l). In the mild 
coagulopathy group, the transfusion of platelet pool not only contributed to 
thrombotic complications at 30-days but had no significant impact (p=0.66) on 
the platelet count of individuals that presented with lower levels (113.5×109/ vs 
95×109/l). The transfusion of platelet pool was only effective in the case of 
severe coagulopathy (n=1). This outcome complements earlier indications for 
the independent transfusion of platelet in any surgical patients with values less 
than 50×109/l in practice, known cases of platelet disorders and severe 
coagulopathy (Van Veen et al., 2010). The other relevant use of platelet, is in 
cases of platelet dysfunction. This commonly occurs in individuals whom 
regularly take medications such as aspirin (Acetylsalicylic Acid) and/ or 
Clopidogrel (thienopyridine anti-platelet). However, evidence suggests that the 
risk of bleeding in such individuals is directly proportional to the volume of the 
medication and may not have the same profound effect as previously thought 
(Schrör, 1997). In addition, if such status is suspected (platelet dysfunction), 
transfusion is not necessarily the only possible option and instead platelet 
function and count during the perioperative period can be measured and 
accordingly adjusted based on clinical and laboratory data. This omits the 
possible adverse outcomes associated with platelet transfusion (fever, 
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transfusion reaction, immune-mediated platelet destruction and thrombosis) 
and helps in evidence driven approach in adjustments of such abnormalities 
(Reddy et al., 2015). Furthermore, recent evidence suggests the impact of 
such medication may not necessarily cause dysfunctional or inhibitory impact 
after all (Bartels et al., 2015).  
 
7.5 Conclusion 
Overall, it appears that empiric and/or protocol driven transfusion of fresh 
frozen plasma does not have any impact on correction of any type 
coagulopathy (mild versus sever) noted in ruptured abdominal aortic 
aneurysms. It should be reserved only for known cases of factor V and VIII 
deficiency. The transfusion of platelet pool does not have any bearing on the 
correction of mild coagulopathy and should be used in severe cases that are 
very rare. 
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CHAPTER 8 
 
Discussion of Thesis 
 
The lack of literature in support of hemostatic resuscitation of ruptured 
abdominal aortic aneurysms (rAAA) and adoption of a protocol derived from 
civilian and military trauma initiated the clinical question and the platform for 
this thesis. A meticulous evaluation of the literature identified two major issues. 
Firstly, the foundation of hemostatic resuscitation in the trauma/military cohort 
is based entirely on the presence of coagulopathy in the vast majority of their 
cohort. This premise was applied to rAAAs without any conclusive and robust 
evidence (Kordzadeh et al., 2016). Secondly, the impact of such transfusion on 
ruptured abdominal aortic aneurysms was never studied nor investigated. 
Simply an assumption was made that hemorrhage in any type of setting 
mimics same presentation and pathophysiology to that of aforementioned 
groups of individuals and should be treated equally.  
 
In order to identify what is the true coagulation status of ruptured abdominal 
aortic aneurysms, a search for a robust definition of the term “coagulopathy” 
was performed. Despite numerous academic definitions, only one applicable 
definition and its sub group terminology in daily practice was identified 
(Greuters, 2011, Hunt, 2014). This search highlighted that coagulopathy could 
be of two major sub types of mild and severe. The mild sub-type only refers to 
a non-significant derangement of coagulation markers that do not necessitate 
and/or require any correction whereas the second subtype (severe 
coagulopathy) demands an immediate and a responsive correction (Greuters, 
2011, Hunt, 2014).  
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The coagulation cascade and its normal physiological process take place 
through two independent and well-defined pathways. These are the extrinsic 
and intrinsic pathways as highlighted in figure 8.1 of this chapter. In order to 
assess both pathways in the entire cascade every hospital and/or unit in the 
world refers and evaluates certain independent markers that are universal. 
Amongst them Prothrombin time (PT) and international normalized ratio (INR) 
remain the markers of extrinsic pathway and activated partial thromboplastin 
time (aPTT) the marker of intrinsic pathway.  Another additional factor that is 
evaluated alongside coagulation profile (PT, aPTT and INR) is platelet count 
(Plt) (Hoffbrand,2006; Pallister, 2010). The platelet is an important constitute of 
blood that plays a vital role in clot formation and/or the coagulation process  
(Berridge, 2006). The normal and universally accepted range for all these 
markers is highlighted in Appendix (Appendix 5) of this thesis.    
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*All numbers refer to various factors.   
Figure 8.1 Simplified coagulation cascade in formation of clot  
through extrinsic & intrinsic facto pathway. 
 
 
With these parameters and definitions in hand I embarked on performing the 
first consecutive cohort study assessing the coagulation status of the ruptured 
abdominal aneurysm on their presentation to emergency services of Mid Essex 
Hospital services NHS trust. The outcome of this study demonstrated that only 
17.1% of patients (n=14/82) with rAAAs present with coagulopathy. Amongst 
them only 7.1% (n=1/14) exhibited significant and/or severe coagulopathy that 
required actual correction. The remaining population had mild coagulopathy 
that did not demand any correction but received correction irrespective. In this 
study I also evaluated the impact of presenting coagulation on both outcomes 
of 30-day morbidity (p=0.51) and mortality (p=0.10) that demonstrated no 
statistical significance.   Due to the outcome of this study being in conflict with 
prior reports and invited commentaries (Davies, 1993; Fransson, 2012) the 
decision was made to perform the first systematic review and meta-analysis of 
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the literature. The total population identified from 1966 to 2015 was 461 
patients. The pooled analysis by calculation of the mean value and variance-
weighted prevalence of coagulation exhibited that the majority (≥ 85%) of 
patients with rAAA do not present with coagulopathy. Only 6% of the entire 
population showed significant and/or severe coagulopathy. This finding 
complemented my primary study outcome of 7.1% (Kordzadeh et al., 2016) 
concluding that rAAAs do not present with coagulopathy and prior assumptions 
in practice held no merit.  
 
Another notable outcome of this systematic review was the elevated levels of D 
dimer or fibrin degradation product (FDP) in 46.2% of the entire population. 
This product (D dimer or FDP) is the component of clot degeneration by 
fibrinolysis and is deployed as a blood marker (test) to determine thrombosis. 
This in turn suggests that 46.2% of patients with rAAA could have an activated 
coagulation cascade rather than coagulopathy that was not noted before. This 
finding in combination to the emerging evidence (Englberger et al., 2006) 
suggests, thrombosis might be a contributing factor to that of morbidity and 
mortality rather than coagulopathy secondary to hemorrhage. Given (in last 
decade) the method of rAAA repair has not altered and has even improved, the 
aforementioned finding (thrombosis) does not take its root from the surgical 
techniques and must have another potentiating source. This in combination 
with outcomes noted in my daily practice initiated the clinical question as to 
whether the new resuscitation strategies (blood and blood component 
transfusion) are contributing to these adverse outcomes (thrombosis resulting 
in mortality and morbidity) that might have not been noted before.    
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Now that it has been established that rAAAs do not present with coagulopathy 
and if they do it only includes a very small proportion (6-7%) and perhaps they 
might have an activated status (hyper coagulate). It remained crucial to 
understand the foundation of massive transfusion protocol in practice and to 
identify why rAAAs might behave different to that of military and trauma cohort.   
 
The current evidence recommends the use of packed red blood cell (PRBC) 
instead of fluids as the first line therapy for the depleted volume of circulation 
as a consequence of hemorrhagic shock in the resuscitation period. This 
practice results in rapid volume expansion, optimizes oxygen transportation 
and/or cardiac cycle with improved survival. However, in the later phase of 
these studies, it was noted that the addition of other blood products such as 
fresh frozen plasma and platelet might also improve survival of trauma patients 
by inhibition of coagulopathy and/or their correction during the resuscitation 
phase. This resulted in recommendation of a 2:1:1 and/or 1:1:1 ratio of blood 
and blood component (fresh frozen plasma and platelet) transfusion for all 
hemorrhagic shock patients including rAAAs (Borgman et al., 2007). However, 
in none of these studies any patient with rAAA was included nor investigated. 
So this raised the clinical question that if rAAAs are not in coagulopathy and 
might be in hyper coagulate status does later addition of such products (fresh 
frozen plasma and platelet pool) contribute to thrombosis or even needed?   
 
Therefore, thesis embarked on investigating the clinical implication of such 
protocol on 30-day morbidity and mortality of rAAAs. The evaluation of blood 
product transfusion on 30-day mortality and morbidity of rAAAs highlighted that 
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the transfusion of > 3 units of fresh frozen plasma (FFP) regardless of blood 
loss and transfusion of packed red blood cell (PRBC) is associated with 
increased mortality (p=0.02) in the rAAA cohort. In addition, transfusion of > 1 
pool of platelet (Plt) independent of blood loss and transfusion of packed red 
blood cells (PRBC), was associated with morbidly as a result of thrombotic 
complications. The result of this (consecutive cohort) study coupled with 
activated coagulation status of rAAA exhibited that earlier blood product 
transfusion ratio might have far different results in rAAAs than that of 
hemorrhagic shock from trauma. It simply highlights that the suggested ratio of 
transfusion (2:1:1) (1:1:1) is not applicable to all patients and such transfusion 
strategies should be based on clinical and laboratory results instead of one 
protocol for all.  
 
Further examination of blood markers other than those associated with the 
coagulation cascade in this cohort of patients (rAAA) identified another unique 
and previously unknown marker of morbidity. This was the neutrophil to 
lymphocyte ratio (NLR). The neutrophil is an immune cell that circulates in the 
blood and is the first cell to respond to an inflammation and/or infection within 
the circulation. Neutrophilia (increase in neutrophil count) has been associated 
with collagen remodeling, direct endothelial cell injury, pro-thrombotic state and 
hypercoagulability in rAAAs (Siminiak, 1995; Madjid, 2004; Coller, 2005). 
Lymphocytes, a subtype of white cell blood count is representative of the 
immune system. Lymphocytopenia (decrease in lymphocyte count) appears to 
be the result of redistribution and margination of lymphocytes within the 
lymphatic system and a marker of accelerated apoptosis (designed cell death). 
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Low lymphocyte count indicates a state of immunosuppression and 
physiological stress (Evans, 1995). The NLR > 5 were associated with 
increased morbidity in rAAAs (p=0.001). Given 50% of morbidity (n=11/22) was 
from thrombotic events, this blood marker demonstrated the active state of 
coagulation, physiological stress and the possible clinical impact of blood 
product transfusion (FFP and Plt) on this group of patients. This marker (NLR) 
remains the cheapest predictor of morbidity in rAAAs to date. It is a very useful 
tool for stratification of this group of patients during their postoperative recovery 
phase.  
 
This thesis did not suffice with the impact of blood transfusion, identification of 
blood markers and base line coagulation of rAAAs. I also investigated the 
impact of such protocols on postoperative markers of coagulation (corrected vs 
non corrected) (Chapter 6). This is a crucial step as to whether (despite all 
outcomes of mortality and morbidity) the primary aim of blood product 
transfusion (FFP and PLT) has been effective in achieving the correction of the 
assumed coagulopathy.  
 
This final study demonstrated that transfusion of blood products (FFP and Plt) 
does not have any (statistical) significant impact on the overall correction of 
coagulation. Out of 14 individuals nine remained coagulopathy post 
transfusion. The only correction was in one case of reported sever 
coagulopathy by platelet transfusion only. It appeared that the transfusion of 
fresh frozen plasma does not have any impact on correction of any type 
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coagulopathy (mild versus sever) in ruptured abdominal aortic aneurysms at all 
and it should be reserved for known cases of factor V and VIII deficiency only.  
 
In conclusion, majority of ruptured abdominal aortic aneurysms do not present 
with coagulopathy and if they do it is not severe. Effort should be made to 
minimize the blood loss at first instance and if transfusion is recommended it 
should be limited to packed red blood cells and in sever advocated case 
platelet pool of limited amount. The fresh frozen plasma has no rule in 
correction of coagulopathy in rAAAs and should be reserved for known 
depleted cases of factor V and VII deficiency.    
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CHAPTER 9 
 
Recommendations for Practice 
 
 
 
This thesis has produced certain results that were now known before in the 
clinical practice and the following conclusion for practice was made: 
 
• No assumption should be made that all ruptured abdominal aortic 
aneurysms presenting to the emergency services are in coagulopathy.  
• All ruptured abdominal aortic aneurysm should have a coagulation 
profile and/or screening on arrival to the emergency services. 
• Only 6-7 % of all ruptured abdominal aortic aneurysm present to 
emergency services with severe coagulopathy.  
• Ruptured abdominal aortic aneurysms present with elevated levels of D 
dimer and/or fibrin degradation product (FDP) in 46.2% of cases. 
• Ruptured abdominal aortic aneurysms might possess a hyper coagulate 
status rather than coagulopathy. 
• If hemostatic resuscitation is indicated, packed red blood cell (PRBC) 
can be transfused and it is evidence based. 
• No additional blood product (Fresh frozen plasma and platelet pool) 
should be transfused as a part of any protocol unless clearly indicated 
through available laboratory results.  
• Platelet pool of more than 1 contributes to thrombotic complications 
independent of any other blood and/or blood component transfusion, 
therefore their use should be limited and subjected to clinical and 
laboratory findings. 
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• The fresh frozen plasma has no rule in correction of coagulopathy in 
rAAAs and should be reserved for known depleted cases of factor V and 
VII deficiency.    
• Fresh frozen plasma (FFP) transfusion of more than 3 units, 
independent of any other blood and/or blood component transfusion can 
contribute to mortality and their use beyond this point should be 
clinically justified.  
• Neutrophil to lymphocyte ratio (NLR) > 5 can be used as a predictive 
marker of morbidity. 
• Neutrophil to lymphocyte ratio (NLR) can be used as risk stratification 
tool to justify longer and closer post-operative monitoring though 
intensive care and/or high dependency unit. 
• Coagulopathy in rAAAs is a complex event and no specific blood 
product transfusion can single handily rectify this cascade and attention 
to other possible products may be required.  
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Recommendations for Future Research. 
 
 
• Protocols derived from different cohorts of patients cannot, in modern 
day practice, be applied to another field of medicine without prior 
investigation.  
• Ruptured abdominal aortic aneurysms (rAAA) possess a different 
cellular, physiological and coagulation status to that of trauma cohort 
and this requires substantive research.   
• A larger number of patients (rAAA) might be needed to complement 
and/or refute the current findings.  
• The possible hyper coagulate status of rAAAs requires further in-depth 
(cellular, molecular and physiological) investigation.  
• Optimal transfusion ratio in rAAAs should await further investigations. 
• All future investigations should attempt to report coagulation in a 
universally accepted manner for optimal collation of the data.  
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Appendix 2. PRIMSA Flow Chart. 
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Appendix 3. Oxford critical appraisal tool for assessing a cohort study.  
12 Questions To Help You Make Sense Of Cohort Study 
How to use this appraisal tool  
Three broad issues need to be considered when appraising a cohort study:  
Are the results of the study valid? What are the results? 
Will the results help locally?  
(Section A) (Section B) (Section C)  
The 12 questions on the following pages are designed to help you think about 
these issues systematically. The first two questions are screening questions 
and can be answered quickly. If the answer to both is “yes”, it is worth 
proceeding with the remaining questions.  
There is some degree of overlap between the questions, you are asked to 
record a “yes”, “no” or “can’t tell” to most of the questions. A number of 
italicised prompts are given after each question. These are designed to remind 
you why the question is important. Record your reasons for your answers in 
the spaces provided.  
These checklists were designed to be used as educational pedagogic tools, as 
part of a workshop setting, therefore we do not suggest a scoring system. The 
core CASP checklists (randomised controlled trial & systematic review) were 
based on JAMA 'Users’ guides to the medical literature 1994 (adapted from 
Guyatt GH, Sackett DL, and Cook DJ), and piloted with health care 
practitioners.  
For each new checklist a group of experts were assembled to develop and pilot 
the checklist and the workshop format with which it would be used. Over the 
years overall adjustments have been made to the format, but a recent survey 
of checklist users reiterated that the basic format continues to be useful and 
appropriate.  
Referencing: we recommend using the Harvard style citation, i.e.: 
Critical Appraisal Skills Programme (2017). CASP (insert name of 
checklist i.e. Cohort Study) Checklist. [online]  
Available at: URL. Accessed: Date Accessed.  
©CASP this work is licensed under the Creative Commons Attribution – Non 
Commercial-Share A like. To view a copy of this license, visit 
http://creativecommons.org/licenses/by-nc-sa/3.0/ www.casp-uk.net  
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(A) Are the results of the study valid?  
Screening Questions  
1. Did the study address a clearly focused issue?  
HINT: A question can be ‘focused’ In terms of  
•   The population studied  
•   The risk factors studied  
•   The outcomes considered  
•   Is it clear whether the study tried to detect a beneficial  
or harmful effect?  
2. Was the cohort recruited in an acceptable way? Yes  
HINT: Look for selection bias which might compromise the 
generalisability of the findings:  
•   Was the cohort representative of a defined population?  
•   Was there something special about the cohort?  
•   Was everybody included who should have been included?  
Is it worth continuing?  
Detailed questions  
3. Was the exposure accurately measured to Yes  
minimise bias?  
HINT: Look for measurement or classification bias:  
o   Did they use subjective or objective measurements?  
o   Do the measurements truly reflect what you want them  
to (have they been validated)?  
o   Were all the subjects classified into exposure groups  
using the same procedure  
Yes Can’t tell No  
Can’t tell No  
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4. Was the outcome accurately measured to Yes ©Critical Appraisal 
Skills Programme (CASP) Cohort Study Checklist 13.03.17  
Can’t tell No  
Can’t tell No 2  
minimise bias?  
HINT: Look for measurement or classification bias:  
•   Did they use subjective or objective measurements?  
•   Do the measures truly reflect what you want them to  
(have they been validated)?  
•   Has a reliable system been established for  
detecting all the cases (for measuring disease  
occurrence)?  
•   Were the measurement methods similar in the  
different groups?  
•   Were the subjects and/or the outcome assessor  
blinded to exposure (does this matter)?  
5. (a) Have the authors identified all important Yes Can’t tell 
No confounding factors?  
List the ones you think might be important, that the author missed.  
(b) Have they taken account of the  
confounding factors in the design and/or analysis?  
HINT: Look for restriction in design, and techniques e.g. modelling, stratified-, 
regression-, or sensitivity analysis to correct, control or adjust for confounding 
factors  
Yes Can’t tell No  
6. (a) Was the follow up of subjects complete Yes Can’t tell No 
enough?  
(b) Was the follow up of subjects long Yes Can’t tell No enough?  
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HINT: Consider 
 The good or bad effects should have had long enough  
to reveal themselves  
•   The persons that are lost to follow-up may have  
different outcomes than those available for assessment  
•   In an open or dynamic cohort, was there anything special  
about the outcome of the people leaving, or the exposure of the people 
entering the cohort?  
(B) What are the results?  
7. What are the results of this study?  
HINT: Consider  
•   What are the bottom line results?  
•   Have they reported the rate or the proportion between  
the exposed/unexposed, the ratio/the rate difference?  
•   How strong is the association between exposure and  
outcome (RR,)?  
•   What is the absolute risk reduction (ARR)?  
8. How precise are the results?  
HINT: Look for the range of the confidence intervals, if given.  
9. Do you believe the results?  
HINT: Consider  
•   Big effect is hard to ignore!  
•   Can it be due to bias, chance or confounding?  
•   Are the design and methods of this study sufficiently  
flawed to make the results unreliable?  
•   Bradford Hills criteria (e.g. time sequence, dose-response  
gradient, biological plausibility, consistency)  
(C) Will the results help locally?  
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Yes Can’t tell No  
 
10. Can the results be applied to the local population? Yes Can’t tell 
No HINT: Consider whether  
•   A cohort study was the appropriate method to answer this question  
•   The subjects covered in this study could be sufficiently different from  
your population to cause concern  
•   Your local setting is likely to differ much from that of the study  
•   You can quantify the local benefits and harms  
11. Do the results of this study fit with other available evidence?  
Yes Can’t tell No  
12. What are the implications of this study for practice?  
HINT: Consider  
•   One observational study rarely provides sufficiently robust evidence 
to recommend changes to clinical practice or within health policy 
decision making  
•   For certain questions observational studies provide the only 
evidence  
•   Recommendations from observational studies are always stronger 
when supported by other evidence  
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Appendix 4.  
National Institute for Health and Care excellence (NICE) Checklist 
(https://www.nice.org.uk/process/pmg10/chapter/appendix-g-
methodology-checklist-qualitative-studies#checklist-6) 
 
Study identification 
Include author, title, reference, year of 
publication 
 
Guidance topic: Key research 
question/aim: 
. 
Checklist completed by:  
 Circle or 
highlight 1 
option for 
each question 
 
Section 1: theoretical approach 
1.1 Is a qualitative approach appropriate? 
For example: 
Does the research question seek to 
understand processes or structures, or 
illuminate subjective experiences or 
meanings (in social care this would apply to 
how care and support is organised and 
service user or carer experience)? Or could a 
quantitative approach better have addressed 
the research question? 
 
Appropriate 
 
Inappropriate 
 
Not sure 
Comments: 
1.2 Is the study clear in what it seeks to 
do? 
For example: 
Is the purpose of the study discussed – 
aims/objectives/research question(s)? 
Are the values/assumptions/theory 
underpinning the purpose of the study 
discussed? 
 
Clear 
 
Unclear 
 
Mixed 
Comments: 
Section 2: study design 
2.1 How defensible/rigorous is the 
research design/methodology? 
For example: 
Are there clear accounts of the 
rationale/justification for the sampling, data 
collection and data analysis techniques 
used? 
 
Defensible 
 
Not defensible 
 
Not sure 
Comments: 
Section 3: data collection 
3.1 How well was the data collection 
carried out? 
For example: 
Appropriate 
 
Inappropriate 
Comments: 
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Are the data collection methods clearly 
described? 
Were the data collected appropriate to 
address the research question? 
 
 
Not sure/ 
inadequately 
reported 
Section 4: validity 
4.1 Is the context clearly described? 
For example: 
Are the characteristics of the participants and 
settings clearly defined? 
Were observations made in a variety of 
circumstances and from a range of 
respondents? 
Was context bias considered (that is, did the 
authors consider the influence of the setting 
where the study took place)? 
 
Clear 
 
Unclear 
 
Not sure 
Comments: 
4.2 Were the methods reliable? 
For example: 
Were data collected by more than 1 method? 
Were other studies considered with 
discussion about similar/different results? 
 
Reliable 
 
Unreliable 
 
Not sure 
Comments: 
Section 5: analysis 
5.1 Are the data 'rich'? 
For example: 
How well are the contexts of the data 
described? 
Has the diversity of perspective and content 
been explored? 
Has the detail of the data that were collected 
been demonstrated? 
Are responses compared and contrasted 
across groups/sites? 
 
Rich 
 
Poor 
 
Not sure/not 
reported 
Comments: 
5.2 Is the analysis reliable? 
For example: 
Did more than 1 researcher theme and code 
transcripts/data? 
If so, how were differences resolved? 
Were negative/discrepant results addressed 
or ignored? 
Is it clear how the themes and concepts were 
derived from the data? 
 
 
Reliable 
 
Unreliable 
 
Not sure/not 
reported 
Comments: 
5.3 Are the findings convincing? 
For example: 
Are the findings clearly presented? 
Are the findings internally coherent (that is, 
are the results credible in relation to the study 
Convincing 
 
Not convincing 
 
Not sure 
Comments: 
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question)? 
Are extracts from the original data included 
(for example, direct quotes from 
participants)? 
Are the data appropriately referenced so that 
the sources of the extracts can be identified? 
Is the reporting clear and coherent? 
 
5.4 Are the conclusions adequate? 
For example: 
How clear are the links between data, 
interpretation and conclusions? 
Are the conclusions plausible and coherent? 
Have alternative explanations been explored 
and discounted? 
Are the implications of the research clearly 
defined? 
Is there adequate discussion of any 
limitations encountered? 
 
Adequate 
 
Inadequate 
 
Not sure 
Comments: 
Section 6: ethics 
6.1 Was the study approved by an ethics 
committee? 
 
Yes 
 
No 
 
Not sure/not 
reported/not 
applicable 
Comments: 
6.2 Is the role of the researcher clearly 
described? 
For example: 
Has the relationship between the researcher 
and the participants been adequately 
described? 
Is how the research was explained and 
presented to the participants described? 
 
Clear 
 
Not clear 
 
Not sure/not 
reported 
Comments: 
Section 7: Overall assessment 
As far as can be ascertained from the paper, 
how well was the study conducted (see 
guidance notes) 
++ 
 
+ 
 
− 
Comments 
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Appendix 5. 
Normal and universally accepted ranges for hematological markers.  
 
 
 
 
 
 
Hematological 
Markers 
The normal range  
Platelet count 
(Plt) 
150 and 450 ×109/l 
Prothrombin time  
(PT) 
10.7 to 13.6 seconds 
International 
Normalised ratio 
(INR) 
0.9 to 1.2 
Activated partial 
thromboplastin time 
(aPPT)  
21.0 to 34.0 seconds  
